Wantstats
IndustriesCompaniesCharts & Stats
Leads DBAdvisoryPricingContact us
Login
/Company Profiles

Deep Intelligence Across Industries

All CompaniesFortune 500Aerospace & Defense iconAerospace & DefenseAgricultureAutomotive iconAutomotiveFinancial Services iconFinancial ServicesChemicals & Materials iconChemicals & MaterialsConsumer Goods iconConsumer GoodsEnergy & Power iconEnergy & PowerEquipment & Machinery iconEquipment & MachineryFood & Beverages iconFood & BeveragesHealthcare & Pharma iconHealthcare & PharmaInformation Technology iconInformation TechnologyManufacturing & ConstructionMRO iconMROProfessional Services iconProfessional ServicesSemiconductors

Showing 14441 companies

Jayex

Jayex Technology Limited

Premium
Information Technology

| Item | Detail | Source | |---|---|---| | Current legal name (listed entity) | Jayex Technology Limited | FY2021 Appendix 4E; ASX | | Former name | Jayex Healthcare Limited (until 31 May 2021) | Market Index former names register | | ABN | 15 119 122 477 | 1H FY2022 Appendix 4D | | Holding company incorporation | 2006, Australia (the ACN 119 122 477 series indicates a 2006 registration; MarketBeat gives "founded 2006") | MarketBeat; ABN | | Operating brand founded | 1978 (Jayex, UK LED information displays) | jayex.com "About"; CB Insights | | Incorporation jurisdiction | Australia (Corporations Act 2001) | 1H FY2022 Appendix 4D, Note 1 | | Registered office / principal place of business (latest disclosed) | Level 4, 100 Albert Road, South Melbourne, VIC 3205 | 1H FY2022 Appendix 4D, Note 1 | | Earlier head office | 17B Cribb Street, Milton, QLD | CB Insights; MarketBeat | | Exchange / ticker | ASX: JTL (formerly JHL); suspended | Market Index | | ASX listing date | 17 December 2015 | Market Index corporate details | | ISIN / CUSIP | ASX ISINs follow the AU0000000XXX format, but the specific code was not confirmed for this dossier. No CUSIP (no US listing). | — | | Fiscal year end | 31 December | Appendix 4E FY2021 | | Employees (latest) | Not publicly disclosed. Proxy: employee benefits expense A$3.15m (FY2020) and A$3.05m (FY2021). | FY2021 Appendix 4E | | Auditor | William Buck Audit (VIC) Pty Ltd | 1H FY2022 review report; Market Index | | Share registry | Automic Group | Market Index | | Shares on issue | 281.28 million (31 Dec 2022 and 31 Dec 2023) | Morningstar via Market Index | | Market capitalisation (current) | About A$0.28m at the last trade of A$0.001; non-tradeable while suspended | Simply Wall St (A$281.3k); Market Index | | Market capitalisation, 31 Dec 2023 | A$2.53m (EV A$6.06m) | Morningstar via Market Index | | Website (listed entity, historical) | jayex.com/en-au/ and jayex.com.au (historical) | Source list; Simply Wall St | | Website (current operator) | jayex.com (© 2026 Jayex Limited) | jayex.com | Jayex is one of the longest-established suppliers of patient-flow technology to UK primary care. Its products cover self check-in kiosks, patient calling displays and waiting-room management. They are sold mainly to NHS GP practices, Primary Care Networks and community trusts on recurring licence-plus-hardware contracts. The listed Australian parent, Jayex Healthcare/Jayex Technology Limited, was assembled in 2015 around the UK business and an Australian appointments app (Appointuit). It later tried adjacent bets, including remote pharmacy dispensing (BluePoint) and a New Zealand medicinal cannabis licence (Whakaora Hou). None reached scale. Revenue never exceeded about A$7.2m. The group was persistently loss-making and relied on related-party funding from its chairman's interests. It exited acute hospital queue management in 2021, and its UK operating company entered administration in August 2024. The franchise survives commercially under private owner Jayex Limited, which claims more than 1,800 UK practices on active subscriptions. For the listed company's equity holders, the investment case has effectively ended. --- ### Company's own description (paraphrased) In its 2020 annual report and its 2021–2022 filings, the company described its principal activities as follows (paraphrased): - providing service technologies to the healthcare industry; and - developing integrated dispensing automation systems for the pharmaceutical and healthcare sectors. After the 2021 divestment of the acute hospital business, the 1H FY2022 report narrowed this focus. Growth would come from UK primary care and NHS community markets through the company's SaaS-based Jayex Connect platform, supported by continued product innovation. Market Index's company profile (drawn from company materials) describes a business evolving to support how patients now want to engage with their GP. That includes social prescribing and care navigation alternatives across primary care. ### Independent characterisation Jayex is best understood as a niche, hardware-enabled vertical SaaS vendor in UK primary-care front-office workflow. Its core value proposition is threefold: 1. **Patient arrival (self check-in):** A touchscreen kiosk (floor, wall or desk mounted) or mobile check-in via SMS link or QR code. It verifies the appointment against the practice's clinical system and marks the patient as arrived. It can also capture or update demographic data such as mobile number and email. 2. **Patient calling:** Screens in the waiting room call patients to clinicians. They show the patient's name or a ticket number, which supports privacy and GDPR compliance, and display health messaging between calls. 3. **Waiting-room visibility and engagement:** A live dashboard of waiting patients (branded QView under Jayex Limited), plus surveys, campaigns, an information hub and reporting. The key technical moat is integration with the UK GP clinical systems: EMIS Web (now Optum), Vision (INPS, now Cegedim) and TPP SystmOne. Each integration requires accreditation and partner status. Jayex was listed as a partner in the EMIS and Vision partner directories, and NHS Digital certified its Enlighten E4 product with TPP SystmOne appointments. Health Tech Newspaper (htn.co.uk) reported that Jayex was at that time the only provider integrated with all three systems for both patient calling and self-arrivals. ### Revenue model | Revenue stream (A$) | 1H2021 | 1H2022 | |---|---|---| | Supply and installation of kiosks (point in time) | 769706 | 1152038 | | Software licences and support services (over time) | 923509 | 1119133 | | Extended warranty (over time) | 132819 | 248625 | | Software development support services (over time) | 4730 | 0 | | Total revenue from continuing operations | 1830764 | 2519796 | The group's revenue in the last period disclosed by product line (1H FY2022) split into four streams: *Source: 1H FY2022 Appendix 4D, Note 5.* Recurring streams (licences and support, extended warranty) were about 54% of 1H FY2022 revenue (derived). Hardware supply and installation made up about 46% (derived). This mix shows a hybrid model: kiosk and screen hardware is sold or installed up front, and multi-year software licences and support produce annuity revenue. Contract liabilities (deferred revenue) were A$1.44m at 30 June 2022, which confirms that customers are invoiced in advance for licences and warranties. Q3 FY2022 commentary reported 883 annual licences billed, up from 776 in Q3 2021 (Stockhead quarterly round-up). ### Value chain position Jayex designs the software and integration layer and sources commercial-grade touchscreens and displays (anti-microbial coated screens are mentioned in partner materials). It also installs, maintains and supports the systems. Jayex Limited emphasises on-site engineer swap-out for failed hardware. It also runs its clinical-system integration on a dedicated Jayex-supplied PC inside the practice network, so that clinical data does not leave the practice. Jayex sits downstream of the clinical-system vendors (EMIS, TPP, Cegedim/Vision), on whom it depends for API access and accreditation. It sits upstream of practices, PCNs, federations and NHS trusts, which buy directly or through NHS frameworks. ### Customer types and end-markets | End-market | Customer types | Status | |---|---|---| | UK primary care | GP practices, PCNs, GP federations, practice groups (e.g., Operose Health, Howbeck Healthcare, Sunderland GP Alliance named on jayex.com) | Core; continued under Jayex Limited | | UK community and acute | NHS community trusts (e.g., Hertfordshire Community NHS Trust), hospital outpatient departments | Community continued; on-premises acute queue management sold to VitalHub in May 2021 | | Australia and New Zealand primary care | GP clinics (integration with MedicalDirector Pracsoft), Appointuit app users | Scaled back in 2022; sales and product roles moved to the UK | | Australian acute | Local Health Districts (e.g., North Sydney LHD QMS with Cerner) | Sold to VitalHub in 2021 | | Pharmacy / dispensing | BluePoint remote dispensing terminals; 2018 licence to Medicann NZ | Dormant / not material | | Medicinal cannabis (NZ) | Whakaora Hou Limited cultivation licence | Sale to Bioarc fell through in 2022; not commercialised |

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1978
South Melbourne, Australia

Unlock Verified Contacts

Access verified employee contacts

Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.

USD650/mo
Buy Now

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
MR
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
BL
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
MI
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
RK
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
JL
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
AM
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Wantstats logo

Move faster. Think smarter. Win bigger.

Join our data driven community.

© 2026 All rights reserved by Wantstats Research and Media Pvt Ltd

footer vector

Pages

  • About
  • News
  • Charts & Stats
  • Contact
  • Ecosystem pricing
  • Privacy policy

Address

Wantstats Research and media Pvt. Ltd, Office No 104, Pentagon 4,
Magarpatta City, Pune - 411028,
Maharashtra, India.

Contact

support@wantstats.com

Follow Us

Follow Wantstats on FacebookFollow Wantstats on InstagramFollow Wantstats on LinkedInFollow Wantstats on YouTubeFollow Wantstats on WhatsApp
Jatcorp

Jatcorp Limited

Premium
Information Technology

Jatcorp is a micro-cap Australian health-and-wellness dairy nutrition company whose identity rests on two assets. The first is a portfolio of lactoferrin-fortified formulated milk powders sold under the Neurio® and Moroka® brands, aimed mainly at Chinese consumers seeking immunity products. The second is the ANMA powder-blending and canning facility in Derrimut, Melbourne, which supports both its own brands and higher-margin OEM contract manufacturing for third parties. In FY2026 it generated A$38.9m revenue (+23%), a A$6.1m audited gross profit and a A$4.7m statutory net loss. Its auditor has flagged a going-concern material uncertainty. Roughly three-quarters of revenue is booked in its Australian segment, much of it with a single customer and likely destined for Chinese cross-border channels. Its largest shareholder (31.3%) is also its exclusive China distributor. The equity story is a turnaround: shrinking the cost base, rebuilding Neurio after a Chinese trademark loss, and growing OEM and Southeast Asian revenue. --- ### Company's own description (paraphrased from 1H FY26 Interim Report, Directors' Report "Principal activities") The company describes itself as an innovation-led producer of dairy and nutrient products in Australia serving Asia-Pacific markets. Its activities fall into two strands. The first strand is innovation and new product development. This means manufacturing a range of consumer formulations for every age group from infants to seniors. The formulations frequently incorporate lactoferrin, which the company positions as supporting immune function, intestinal health and related benefits. The second strand is brand development. This centres on the flagship brands Neurio® and Moroka®. It covers marketing and promotion and the sale of both proprietary and client products. Distribution is multi-channel, spanning traditional retail and e-commerce, with Australia and China as the primary markets. In ASX boilerplate, the company calls itself a leading producer of supplementary food and plant-based products (CEO appointment announcement, 15 September 2025). ### Independent characterisation Jatcorp is best understood as a small vertically integrated nutritional-powder brand owner and contract manufacturer whose end-demand is overwhelmingly Chinese. It does not farm milk or produce lactoferrin; it buys dairy bases and functional ingredients, then blends, cans and packs them at ANMA. It sells its own brands to distributors and e-commerce operators, and sells manufacturing capacity to other brand owners on an OEM basis. **Value-chain position** - Upstream: purchased milk powders, lactoferrin, IgG, vitamins and minerals, and packaging (raw materials A$2.22m and packaging A$1.19m of inventory at 30 June 2026). - Midstream: blending and canning at ANMA. - Downstream: sale to distributors and cross-border e-commerce (CBEC) operators, principally the HS Group (HS Global E-Commerce (HK) Limited / "H&S International"), plus Australian, New Zealand, Hong Kong and Vietnamese channels. **Revenue model** - 100% of FY2026 revenue is "goods transferred at a point in time" (FY2026 Preliminary Financial Report, Note 4). There is no subscription, licensing or service revenue line. - The mix splits between own-brand product sales (Neurio, Moroka, Jinvigorate and others) and OEM manufacturing revenue (e.g., BTNature, a Taiwan client, and the new India-bound customer). - The precise branded-versus-OEM split is not publicly disclosed. **Commercial structure worth noting** - Large customer prepayments (contract liabilities of A$4.22m at 30 June 2026). Customers paid A$18.94m in advance during FY2026 (Note 10). - A trade promotion expense (TPE) payable to the HS distributor as a fixed percentage of sales. From FY2026 this is netted against revenue (Note 2). - A share-based sales incentive plan with a distributor (1,000,000 shares issued 2 September 2025). **Customer types** - Distributors and wholesale partners (largest category). One Australian-segment customer contributed A$23.64m (60.8%) of FY2026 revenue, and one China-segment customer A$5.03m (12.9%) (Note 3, Major customers). - E-commerce platforms. Historic flagship stores on Tmall Global, JD Worldwide/JD Global and Pinduoduo were operated before the company terminated its own China online store operations in Q4 FY2026 (Kalkine summary of Q4 FY26 4C). - Bricks-and-mortar mother-and-baby stores in China (Moroka in approximately 150 stores, 1H FY26), plus stores in Hong Kong and Vietnam. - OEM brand-owner customers using ANMA capacity. **End-markets served** - Paediatric and maternal nutrition (formulated milk powders for children). - Adult and senior immunity and wellness powders. - Medical-adjacent nutrition (Jinvigorate Diabetic Formula, low-GI certified). - OEM nutritional powders for third-party brands.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2006
Sydney, Australia
Jameson

Jameson Resources Limited

Premium
Information Technology

Jameson Resources is an ASX-listed, pre-production steelmaking coal developer whose value rests almost entirely on one asset: the Crown Mountain Hard Coking Coal Project in British Columbia's Elk Valley, the most important seaborne hard coking coal district outside Queensland. It holds the project through a majority-owned Canadian subsidiary in partnership with Bathurst Resources. The 2025 Feasibility Update confirmed a 57.5 Mt run-of-mine reserve and a 15-year mine life. It reported a pre-tax NPV10 of US$942 million and a post-tax NPV of US$527 million against pre-production capital of US$394 million. In May 2026, Crown Mountain became the only Canadian steelmaking coal project to reach the final joint provincial-federal environmental assessment stage. Jameson's investment case is therefore a permitting-and-funding story. It has no revenue, funds itself through frequent small equity raises, and has a market capitalisation of under A$50 million against a project NPV more than ten times larger. That gap reflects regulatory, Indigenous-consent, financing and coal-market risk. --- **Company's own description.** In its half-year report for the period ended 31 December 2025, Jameson describes itself as focused on developing a potentially low-cost, high-quality steelmaking coal operation from its Crown Mountain Project in south-east British Columbia. It says it is being progressed through permitting toward a Final Investment Decision and eventual development together with a subsidiary of Bathurst Resources Limited (ASX: BRL). Earlier corporate descriptions call Jameson an independent, growth-oriented steelmaking coal developer specialising in low-cost, high-quality open-cut mining. Market Index describes the company more broadly as focused on acquiring, exploring and developing strategic coal projects in western Canada. **Independent characterisation.** Jameson is a single-asset, permitting-stage development company. It does not mine, process or sell coal. Its operations consist of: 1. Managing and funding the environmental assessment (EA) of Crown Mountain under joint British Columbia and federal Canadian processes. 2. Negotiating consent and benefit agreements with the Yaq̱it ʔa·knuqⱡi'it First Nation (YQT), on whose unceded territory the project sits. 3. Maintaining and updating the technical case (the 2020 Bankable Feasibility Study, the 2021 Yield Optimisation Study and the 2025 Feasibility Update). 4. Marketing future production to steelmakers (Japanese, Korean and Indian mills are named in 2025–26 quarterly reports) for offtake and possibly equity. 5. Raising equity capital to fund all of the above. **Business model.** Jameson currently has no business model in the operating sense. Its implied future model is that of a seaborne metallurgical coal producer. It would sell premium hard coking coal (HCC) FOB Vancouver under term contracts and spot sales, priced off the benchmark Premium Low-Vol HCC index. Before Final Investment Decision (FID), value would be realised through project equity sell-downs, strategic investment, offtake-linked prepayments or a corporate transaction. **Revenue model mix.** Product: 0%. Service: 0%. Subscription: 0%. Licensing: 0%. Reported "revenue" consists entirely of interest and other minor income: A$47.9 thousand in FY2025 (TipRanks, extracted from the FY2025 Annual Report). **Value-chain position.** Upstream (resource ownership and development). Once operational, Crown Mountain would cover mining, coal handling and preparation, and rail and port logistics through third-party infrastructure (Canadian Pacific rail lines and British Columbia's west-coast deepwater coal terminals). **Customer types and end-markets.** The future customer base is integrated blast-furnace steelmakers, chiefly in Asia (Japan, Korea and India) as identified in 2025–26 marketing activity. Jameson's August 2026 investor presentation specifically emphasises demand growth in India. The end-market is global blast-furnace (BF-BOF) steel production.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2007
Sydney, Australia
Antimony

Antimony Resources Limited

Premium
Information Technology

| Field | Detail | Source | |---|---|---| | Current legal name | Antimony Resources Limited | SmallCaps, Sep 2026; Market Index | | Current ASX ticker | ANT (trading from 21 September 2026) | SmallCaps, Sep 2026 | | Former names (most recent first) | EV Resources Limited (EVR, Dec 2021–Sep 2026); Jadar Resources Limited (JDR, Dec 2019–Dec 2021); Jadar Lithium Limited (JDR, ~Jan 2018–Dec 2019); South East Asia Resources Limited (SXI, to Jan 2018); Victory West Metal Limited (VWM, to Dec 2012); Victory West Moly Limited (VWM, to Apr 2011); Richfield Group Limited (RCH, to Feb 2009); Worldwide Technology Group Limited (WWT, to Dec 2002); Oka Motor Company Limited (OKA, to Dec 1999) | Market Index former-name register; Business News | | ABN | 66 009 144 503 | H1 FY2026 Interim Report | | Founding / incorporation year | 1985 | MarketBeat, StockAnalysis company profiles | | Incorporation jurisdiction | Australia (domiciled in Australia; state of registration not confirmed in sources reviewed) | H1 FY2026 Interim Report, Note 1(a) | | ASX listing date | 7 December 1994 | Market Index | | Headquarters / registered office | 311–313 Hay Street, Subiaco, Western Australia 6008; Tel +61 8 6489 0600 | H1 FY2026 Interim Report; 14 Sep 2026 ASX release | | Other listings | Frankfurt (R1E.F), Berlin (R1E.B), Stuttgart (R1E.SG) per company corporate directory; StockAnalysis lists Frankfurt code as R1EA (discrepancy noted) | H1 FY2026 Interim Report; StockAnalysis | | ISIN / CUSIP | Not publicly verified in this research (ISIN may have been reissued on the 2026 consolidation/name change); no CUSIP (not US-listed) | — | | Fiscal year end | 30 June | H1 FY2026 Interim Report | | Employees | Not publicly disclosed (company operates with a small executive team, contractors and Mexican site staff) | — | | Auditor | Grant Thornton Audit Pty Ltd, Perth (review partner B P Steedman) | H1 FY2026 Interim Report | | Share registry | Automic (formerly Advanced Share Registry per older data) | H1 FY2026 Interim Report; Market Index | | Banker | National Australia Bank | H1 FY2026 Interim Report | | Website | www.evresources.com.au (EV-era domain); legacy www.jadar.com.au no longer the corporate site | 14 Sep 2026 ASX release | | Market capitalisation (current) | Approx. A$13.4m–A$14.0m (October 2026) | Simply Wall St (ASX:ANT page) | | Last verified share price | A$0.041 (close 25 Sep 2026, post 10:1 consolidation) | StockAnalysis (ASX:ANT) | | Metric | FY2023 | FY2024 | FY2025 | |---|---|---|---| | Employees (headcount) — not publicly disclosed | — | — | — | Headcount is not disclosed in any filing reviewed. The H1 FY2026 segment note records only A$50,000 of "employment" cost in the corporate segment for the half, indicating that most personnel costs run through consulting, director fees and share-based payments rather than payroll. Antimony Resources Limited is a Perth-headquartered micro-cap that has spent four decades cycling through business identities — motor vehicles, technology, molybdenum, Serbian lithium, Peruvian gold and Americas copper — before concentrating, from 2025, on antimony. Its current thesis is a "processing-first" route to cash flow: a leased-with-option 150 tonne-per-day mill at Tecomatlán, Puebla, Mexico, refurbished for flotation and gravity recovery and fed initially by third-party high-grade ore under a binding five-year supply agreement (Chinantla) and additional regional feed (Vinatas). Behind the plant sits the 70%-owned Los Lirios antimony project in Oaxaca, where a maiden JORC resource is targeted for Q4 CY2026, and two 100%-owned Nevada antimony claim groups (Dollar and Milton) giving US critical-minerals optionality. The company is pre-revenue, carries a going-concern material uncertainty, and funds itself through frequent small equity raises. It offers high-risk, binary exposure to Western antimony supply-chain security. --- ### What the company does Antimony Resources is a mineral exploration and development company. Its stated principal activity in the H1 FY2026 Interim Report is mineral exploration and development aimed at addressing the structural deficit in global antimony supply, via projects in Mexico and the United States. In practical terms, the business in late 2026 comprises three linked activities: 1. **Toll-style / ore-purchase processing (Tecomatlán, Mexico).** The company controls, via a 12-month lease with a US$1.8 million purchase option (subsequently restructured to a milestone-based structure with a reported US$10,000 upfront payment), a 150 tpd processing plant with crushing, three ball mills and flotation cells. It is completing a production-capable "proof-of-concept" campaign on a 200-tonne high-grade ore parcel and intends to buy third-party ore from regional artisanal and small-scale miners, produce antimony concentrate, and sell it to traders or smelters. 2. **Exploration and resource definition (Los Lirios, Mexico; Dollar and Milton, Nevada; residual Peru/Austria/Australia interests).** Los Lirios (70% via joint-venture company Exploraciones Mineras los Lirios) is intended as a future proprietary feed source. 3. **Portfolio recycling.** Over 2025 the company sold non-core assets (La Cienega, Coyote Creek, Khartoum, Yanamina) for cash, shares and royalties, retaining NSR royalties on several. ### Business and revenue model | Revenue stream | Status (Oct 2026) | Model | Disclosure | |---|---|---|---| | Antimony concentrate sales | Pre-revenue; first concentrate targeted 2H CY2026 | Product sales; benchmark-linked pricing contemplated in ore-supply and offtake terms | 6 Aug 2026 and 14 Sep 2026 ASX releases | | Third-party ore processing margin | Pre-revenue | Purchase ore at benchmark-linked prices, process, sell concentrate (merchant processing) | 6 Aug 2026 ASX release | | Royalties | Non-producing | 1% NSR (Khartoum), 2% NSR (La Cienega), retained royalty (Coyote Creek) | H1 FY2026 Interim Report; news reports | | Asset sale consideration | Episodic | Cash/share proceeds from divestments (e.g., A$700k Khartoum; US$6m staged Yanamina) | H1 FY2026 Interim Report | | Interest income | Immaterial | A$4,653 in H1 FY2026 | H1 FY2026 Interim Report | Product vs service vs subscription vs licensing mix: 100% prospective product (concentrate) revenue; no service, subscription or licensing revenue. Recorded revenue in FY2025 was approximately A$0.02 million (S&P data), essentially interest/other income. ### Value-chain position The company sits in the upstream and midstream of the antimony chain: ore sourcing (own exploration plus third-party purchase) and beneficiation into a concentrate (target grades of roughly 42%–68% Sb demonstrated in testwork). It does not smelt or refine at commercial scale, though it has run small direct-to-smelter test melts producing antimony ingots at a third-party facility in Guadalajara (reported February 2026). Downstream customers would be traders (an MOU with Wogen and XCLR contemplated 100% offtake and up to US$3 million of production-linked funding) and smelters/refiners serving flame-retardant, lead-acid battery, alloy and defence end-markets. ### Customer types and end-markets | Customer type | Status | Notes | |---|---|---| | Commodity traders | MOU stage (Wogen/XCLR, non-binding, 2025) | Offtake plus production-linked funding concept | | Smelters / refiners | Discussions ("several positive discussions" per 14 Sep 2026 release) | No binding offtake disclosed | | US government-linked programmes | Engagement via MineMaker LLC (2026) | Target agencies cited: US Department of Energy, Department of War, Export-Import Bank | End-markets ultimately served by antimony: flame retardants (antimony trioxide), lead-acid battery alloys, ammunition and defence materials, glass and ceramics, semiconductors and emerging energy-storage chemistries. Antimony is designated a critical mineral by the US, the EU and Australia (company releases, 2026). ### Company's own description vs independent characterisation **Company description (paraphrased from 14 September 2026 ASX release):** a critical minerals exploration and development company focused on securing the North American antimony supply chain, rapidly transitioning from diversified explorer to expected near-term producer, building an integrated platform of regional ore supply and processing at Tecomatlán, potential future proprietary feed from Los Lirios, and direct US exposure through Nevada assets. **Independent characterisation:** a pre-revenue, cash-constrained micro-cap whose near-term value hinges on proving a small merchant-processing operation in Mexico using third-party ore. The "integrated North American platform" language is aspirational: the Nevada assets are early-stage claim groups with rock-chip results only; Los Lirios has no JORC resource yet (target date has already slipped from Q3 to Q4 CY2026); and the plant is not yet wet-commissioned at full-flowsheet scale. The company's history of repeated strategic pivots and serial name changes is a material governance and credibility consideration for investors.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1985
Subiaco, Australia
Jacobson

Jacobson Pharma Corporation Limited

Premium
Information Technology

Jacobson Pharma is Hong Kong's largest locally based, vertically integrated generic-drug manufacturer. It runs nine licensed pharmaceutical production facilities in Hong Kong, an SAP-driven central warehouse and its own truck fleet, regulatory, quality and sales operations. Around 97% of revenue comes from Hong Kong, and roughly half from one major customer, almost certainly the Hospital Authority, which runs the public hospital system. Since spinning off and then fully distributing its branded consumer-health arm (JBM Healthcare) in 2021–2023, it has become a focused "essential medicines and specialty drugs" company. Its growth levers are a 241-product generics pipeline, an aggressive in-licensing programme (46 deals in FY2026), biosimilars, and a niche position as one of only two licensed CAR-T handlers in Hong Kong. Earnings quality is high: 43% gross margin, 34.5% adjusted EBITDA margin, and HK$301.6m attributable profit in FY2026. The equity trades at about 6.4x trailing earnings, with a founder who controls about 70% of the shares. --- ### Company's own description (AR FY2026, paraphrased) The company calls itself a leading Hong Kong pharmaceutical company that is vertically integrated across research, development, production, sale and distribution of essential medicines and specialty drugs. It says it is a major provider of generic drugs in Hong Kong, with one of the widest sales and distribution reaches into both the Public Sector (Hospital Authority and Department of Health) and the Private Sector (private hospitals, clinics, doctors in private practice and registered pharmacies). It is also expanding into selected Asian markets. It runs 9 licensed production facilities in Hong Kong and manages its own warehousing, logistics, regulatory, quality control, and sales and marketing functions. Its stated vision is to become a leading player in essential medicines, specialty drugs and healthcare solutions in Greater China and Asia. The AR FY2026 lists four competitive strengths: 1. Leadership across a wide range of essential and specialty drugs in Hong Kong, including respiratory, cardiovascular, central nervous system (CNS), gastrointestinal and oral anti-diabetic medicines, with a strategic tilt toward specialty drugs and biosimilars. 2. R&D capability that the company says leads Hong Kong generic manufacturers by number of new drug registrations in recent years, plus partnerships with local and overseas research institutions. 3. Sales and distribution covering substantially all Public and Private Sector institutions and registered pharmacies. 4. Logistics infrastructure that includes a central distribution centre, a high-capacity truck fleet, and specialised vaccine and Advanced Therapy Product (ATP) cold-chain capability. ### Business model and revenue model | Revenue stream | Nature | Disclosure status | |---|---|---| | Manufactured generic drugs (own registrations) | Product sales to the Public Sector (mostly via tenders and contracts) and the Private Sector | Not split out; the bulk of revenue | | In-licensed specialty drugs, biologics, biosimilars and vaccines | Product sales of partner products under exclusive HK/Macau licences | Not split out | | Logistics, supply-chain and patient-support services (e.g., Yikaida CAR-T) | Service fees for ATP cold-chain, logistics, sales and marketing support | Not split out; believed small | | e-Jacob Pharma2U digital ordering | Channel for product sales to 1,200+ clinics | Not a separate revenue line | | Rental and licence income (e.g., licence of Tai Po factory space to JBM's Europharm HK) | Other income | HK$247,000 a month under the Oct 2025 agreement | | Licensing out / royalties | Not disclosed | Not publicly disclosed | | Subscription | None | — | Product sales make up essentially all revenue. The group reports one operating segment ("essential medicines and specialty drugs"), so the product/service/licensing mix is not publicly disclosed in numbers. ### Value-chain position Jacobson covers the full value chain for off-patent medicines in Hong Kong: formulation and pre-formulation R&D, stability studies and dossier registration with the Pharmacy and Poisons Board, PIC/S-GMP manufacturing across solid, semi-solid, liquid and sterile (eye drops and injections) dosage forms, warehousing, logistics and direct field sales. For in-licensed innovative and specialty medicines it acts as local marketing authorisation holder, importer, distributor and patient-services provider. Raw materials (active pharmaceutical ingredients and excipients) are bought from approved vendors. Material costs were 41% of cost of sales in FY2026. ### Customer types and concentration **Public Sector:** One customer accounted for more than 10% of revenue: HK$800.8m in FY2026 (≈51.0% of revenue), up from HK$757.2m in FY2025 (≈48.0%). The customer is not named, but given Hong Kong's market structure it is almost certainly the Hospital Authority (inference). **Private Sector:** Private hospitals, general practitioners, specialists, dentists, veterinarians (through e-Jacob Pharma2U) and registered pharmacies. **Regional customers:** Macau (HK$31.6m), Chinese Mainland (HK$23.3m) and other markets (HK$0.2m) in FY2026. ### End markets served Hong Kong prescription pharmaceuticals (public and private), the Macau pharmaceutical market, limited Mainland China sales (cold and flu and gastrointestinal lines), Greater Bay Area designated hospitals (Arsenic Trioxide Oral Solution approved for GBA use in 2022), and a new veterinary diagnostics niche (an in-licensed DNA test for animal cancer treatment options, FY2026). ### Independent characterisation Jacobson is best seen as a Hong Kong-centric, quasi-utility supplier of essential generics to a single-payer public system, with an expanding specialty in-licensing "platform" on top. Its economics rest on registration barriers (Hong Kong's small market discourages multinational generic makers from registering low-value molecules), tender scale and local manufacturing credibility. The 2023 removal of the consumer-brands business (JBM) made the earnings stream lower in growth but more defensive and higher in margin. The main strategic questions are (i) how dependent it is on Hospital Authority tender pricing, (ii) whether in-licensed specialty and biosimilar products can offset seasonal volatility in cold and flu demand, and (iii) whether the HK$600m+ Tai Po smart-factory capex will earn its cost of capital.

Revenue$0.2B
Employees1,768
Market Cap$0.3B
FoundedN/A
Cayman Islands
Cemindia

Cemindia Projects Limited

Premium
Information Technology

Cemindia Projects Limited is a Mumbai-headquartered heavy-civil engineering, procurement and construction contractor whose operating history in India dates to 1931. It is today one of a small group of Indian contractors pre-qualified across the full spectrum of technically demanding infrastructure: rubble-mound breakwaters and deep-water berths, tunnel-boring-machine underground metro, integrated airport terminals, pumped-storage hydro and railway tunnelling, heavy industrial civil works, and — since FY25 — turnkey data centre EPC. The FY26 financial year was the most consequential in its modern history: the ninety-year-old Thai-controlled contractor became an Adani Group portfolio company, changed its name, crossed ₹10,000 crore of revenue for the first time, and secured record order inflows of ₹14,821 crore. As at 30 June 2026 its consolidated order book stood at an all-time high of ₹31,307 crore, roughly three times FY26 revenue. The strategic logic of the change of control is straightforward and already visible in the numbers: Cemindia has become the preferred civil-execution arm for a promoter group deploying capital across ports, airports, data centres, thermal and renewable power, roads and water — while retaining an open-market franchise in metro, marine and government work that accounted for the majority of its backlog. --- ### The company's own characterisation The FY26 Annual Report describes the business as follows: *"Cemindia Projects Limited builds on an enduring engineering legacy that has supported India's infrastructure expansion for decades. FY 2025-26 marked a new chapter in our journey as we got integrated within the Adani Group ecosystem."* The Company states it operates across maritime structures, metro rail, airports, highways, bridges and flyovers, industrial structures and buildings, hydro dams, tunnels and irrigation, water and wastewater, foundation and specialist engineering, and data centre, supported by *"deep engineering expertise and disciplined project management."* Its stated vision is *"a satisfied client, a strong and proactive workforce and quality product finished on time maintaining highest safety standards and to budget,"* and its mission is *"to make Cemindia Projects Limited, the country's leading construction Company in customer choice, quality and safety."* The Company's own investment case rests on six declared pillars: robust execution track record; technology and digital innovation; a diversified order book; consistent financial performance; alignment with infrastructure megatrends; and strategic Adani Group synergies. ### Independent characterisation Cemindia is best understood as a pure-play, asset-light, fixed-price civil EPC contractor operating at the technically complex end of the Indian construction market. It is not a developer: it takes no concession risk, holds no BOT/HAM annuity portfolio of consequence, and does not carry the balance-sheet burden of road SPVs that weighs on several listed peers. Revenue is recognised on percentage-of-completion under Ind AS 115 against milestone-based and progress-based billing. There is no product revenue, no subscription revenue and no licensing revenue — the revenue model is 100% project services, delivered through item-rate, lump-sum and design-build contracts. Three characteristics differentiate the franchise: **First, capability moat over price moat.** The segments where Cemindia earns its best economics — breakwaters, deep-water berths, TBM-driven underground metro, pumped-storage hydro, railway tunnelling in Himalayan geology — have short qualified-bidder lists. Pre-qualification typically requires demonstrated completion of comparable scope, owned specialist plant, and marine/geotechnical engineering depth that cannot be rented. The Company's owned fleet as at December 2025 comprised 7 tunnel boring machines, 3 micro-TBMs, 5 trench cutters, 49 hydraulic piling rigs, 3 jack-up barges, 120 cranes, 42 batching plants and 9 twin-boom jumbo drills. That fleet is the moat. **Second, a negative-working-capital operating model.** Cemindia has run a structurally negative cash conversion cycle for a decade, funded by extended supplier credit and mobilisation advances. This is the reason a contractor with ₹10,061 crore of FY26 revenue operates on gross debt of only ₹1,001 crore. It is also the model's principal fragility: the negative cycle is a liability-funded position, not a cash position, and it inverts quickly if payment cycles from government counterparties elongate. **Third, a bifurcated client base that has just shifted.** In December 2025 the order book was 44% government, 8% PSU and 48% private. By March 2026 it had moved to 36% government, 6% PSU and 58% private — a direct consequence of Adani-ecosystem awards. Management indicated on the Q3 FY26 call that group-entity work was approximately 27% of the order book, with a stated FY26 target of roughly 20% and earlier guidance of 25–26%. This is now the single most important structural variable in the equity story: it simultaneously reduces receivable risk and government-payment-cycle risk, while introducing related-party concentration and pricing-transparency risk. ### Value chain position and end markets Cemindia sits in the execution tier of the infrastructure value chain — downstream of the concessionaire/asset owner and the design consultant, upstream of specialist subcontractors and material suppliers. It performs its own design on design-build packages, procures and installs, and self-performs the technically critical scope (tunnelling, marine piling, diaphragm walling) while subcontracting commoditised civil and finishing work. Subcontracting expense of ₹2,900 crore in 9M FY26 against construction materials consumed of ₹2,334 crore indicates a labour-and-subcontract-heavy cost structure, which is the normal shape for an Indian heavy-civil contractor and provides operational flexibility but limits gross-margin ceiling. End markets served: ports and maritime logistics; urban mass transit; civil aviation; national and state highways; steel, power, mining and petrochemical industrial capex; hydro and pumped storage; irrigation and water conveyance; municipal water and wastewater; and, newest, hyperscale/colocation data centres. Customer types: central and state government departments and ministries (CPWD, Military Engineer Services, state irrigation departments); metro rail corporations (Chennai, Mumbai, Kolkata, Bengaluru, Maharashtra Metro, Rail Infrastructure Development Company Karnataka); central PSUs (Petronet LNG, IRCON, SAIL, IOCL); private industrial and infrastructure groups (Adani Ports & SEZ, Adani Infra, Adani Enterprises, Adani Green, Adani Road Transport, ArcelorMittal Nippon Steel, JSW, Ingka Centres/IKEA, Korba Power, Bengal Bonded Warehouse, Mindstone Mall Developers); municipal bodies (Ahmedabad Municipal Corporation, MCGM); and overseas clients (Colombo West International Terminal, Power Grid Company of Bangladesh, NMDC Group in Abu Dhabi).

Revenue$1.2B
EmployeesN/A
Market CapN/A
Founded1931
Maharashtra, India
Atlantic

Atlantic Lithium Limited

Premium
Information Technology

Atlantic Lithium is a pre-revenue, West Africa-focused hard-rock lithium developer. Its value rests almost entirely on the Ewoyaa spodumene project in Ghana's Central Region, which the company discovered in 2018. Ewoyaa has a JORC Mineral Resource of 36.8Mt at 1.24% Li2O, 81% of it in the Measured and Indicated categories. Its 2023 Definitive Feasibility Study (DFS) outlined 3.6Mt of spodumene concentrate over a 12-year mine life, with initial capex of US$185m. Ewoyaa holds the first lithium Mining Lease in Ghana to be both granted (October 2023) and ratified by Parliament (March 2026). The project sits within 1km of the N1 highway, 110km from Takoradi port and next to grid power, which gives it an unusually strong infrastructure position among African lithium developments. The company also holds 100%-owned exploration ground in Côte d'Ivoire. In 2026 the board chose a cash exit to Huayou over standalone development. The equity is therefore best seen as a merger-arbitrage instrument anchored at US$0.25486 per share, with standalone downside if the Scheme fails. --- **Company's own description (AR2026).** Atlantic Lithium describes itself as a lithium-focused exploration and development company advancing Ewoyaa through to production to become Ghana's first lithium-producing mine. Its stated position is that Ewoyaa has been advanced through resource delineation, technical studies and permitting to become one of the world's most advanced pre-construction hard-rock lithium projects. In parallel, the company says it is using its technical expertise and regional operating experience to explore its wholly owned Côte d'Ivoire portfolio at low cost. **Independent characterisation.** Atlantic Lithium is a single-asset development company with an exploration option attached. It has no operating revenue. All reported "income" consists of minor fair-value gains, interest and other receipts (FY2026: A$0.34m in total). Its economic model is to: 1. Discover and define lithium pegmatite resources in under-explored Birimian terrain. 2. Complete feasibility work and permitting to de-risk the asset. 3. Fund construction through a mix of: - partner earn-in capital (Piedmont/Elevra: US$17m for studies plus the first US$70m of development capex); - sovereign co-investment (Ghana's Minerals Income Investment Fund (MIIF): US$32.9m agreed); - equity facilities (Long State Investments; Ghanaian pension funds). 4. Eventually sell spodumene concentrate (6% and 5.5% Li2O) plus a secondary DMS by-product and possibly feldspar. At least 50% of output was historically committed to Piedmont/Elevra; Huayou would assume those rights under the Novation Agreement. **Revenue model mix.** **Value chain position.** Upstream mining and beneficiation only. The planned process is open-pit mining → 3-stage crushing → Dense Media Separation (DMS) → spodumene concentrate, trucked to Takoradi port. The concentrate is described in the DFS as suitable for carbonate, sulphide or hydroxide conversion. **Customer types and end-markets.** The future customers are lithium chemical converters and integrated battery-materials groups. Historically this meant Piedmont Lithium, which planned to feed a Tennessee hydroxide plant; prospectively it means Huayou's cathode and precursor supply chain. The ultimate end-markets are electric vehicles (EV) and battery energy storage systems (BESS).

RevenueN/A
EmployeesN/A
Market Cap$0.2B
Founded2007
Sydney, Australia
Irongate

Irongate Group

Premium
Information Technology

| Item | Detail | |---|---| | Entity profiled (primary) | Irongate Group — stapled group comprising Irongate Property Fund I (IPF I, ARSN 162 067 736) and Irongate Property Fund II (IPF II, ARSN 644 081 309) | | Responsible Entity | Irongate Funds Management Limited (ACN 071 514 246; AFSL 290 909) | | Current status | Delisted (ASX removal effective close of trading 18 July 2022; JSE delisting per scheme booklet s.6.7) following acquisition by Charter Hall PGGM Industrial Partnership No.2 (IPF I) and Charter Hall Holdings Pty Limited (IPF II) | | Successor operating entity | Irongate Group (private real estate fund and asset manager), a 50:50 joint venture with Burstone Group (JSE: BTN, formerly Investec Property Fund) since 2023 | | Former names | Investec Australia Property Fund (IAPF) — renamed Irongate Group in 2020 on internalisation of management | | Founding year | Fund listed October 2013 (JSE); management team origins in Investec Group's Australian and New Zealand property business, with a track record pre-dating the listing | | Incorporation / domicile | Australia — registered managed investment schemes (ASIC); IPF I additionally registered as a foreign collective investment scheme in South Africa under the Collective Investment Schemes Control Act No.45 of 2002 | | Headquarters | Sydney, NSW, Australia | | Former exchanges & tickers | ASX: IAP (listed 28 May 2019 – 18 July 2022); JSE: IAP (listed October 2013 – July 2022); Bermuda Stock Exchange secondary listing (terminated in connection with ASX listing, 2019) | | ISIN | AU0000046005 (stapled security, per SENS announcements 2021–2022) | | CUSIP | Not applicable / not publicly disclosed | | Fiscal year end | 31 March | | Employees | Not publicly disclosed (internally managed team after 2020; headcount not disclosed in reviewed sources) | | Auditor | — | | Market capitalisation (current) | Not applicable — delisted. Implied equity value at the scheme price of A$1.90 per stapled security | | Website | http://irongategroup.com.au (now the website of the private Irongate funds management business) | | JSE sponsor / investment bank | Investec Bank Limited | | Legal adviser on take-private | King & Wood Mallesons (for Irongate) | Irongate Group was a dual-primary-listed (ASX/JSE), internally managed Australian real estate investment trust holding a diversified portfolio of metropolitan office and industrial properties across Australia and New Zealand, valued at approximately A$1.68 billion at 31 March 2022. It began life in October 2013 as Investec Australia Property Fund, the first inward-listed Australian property fund on the JSE, offering South African investors hard-currency exposure to Australasian commercial real estate. After an ASX primary listing in May 2019 and the internalisation of management from Investec Group in 2020, it repositioned as an independent, internally managed REIT with ambitions to build a third-party funds management platform. Its value-focused strategy, tilt toward industrial assets and disciplined capital management attracted takeover interest from 360 Capital and ultimately Charter Hall/PGGM, which acquired it for A$1.90 cash per security in July 2022. The Irongate brand and team continue as a private manager backed by Burstone Group. --- ### What the company did (listed era, 2013–2022) Irongate Group owned, managed and selectively developed income-producing commercial real estate in Australia and New Zealand. Its portfolio was concentrated in two sectors — metropolitan/suburban office and industrial/logistics — with a historical mandate (as IAPF) to invest in office, industrial and retail properties. At the time of its 2019 ASX listing the fund held 28 properties (Money Management, May 2019); by March 2022 its portfolio was valued at about A$1.68 billion (SIA announcement, 30 March 2022), including at least one New Zealand asset (100 Willis Street, Wellington). CEO Graeme Katz characterised the portfolio as largely comprising metropolitan office and industrial properties, which he described as two of the better-performing sectors of the Australian commercial property market over FY2021 (Business Day, 5 May 2021). ### Business model and revenue model | Revenue stream | Description | Approximate share of revenue | |---|---|---| | Property rental income | Gross rents from office and industrial tenants under typically multi-year net or gross leases, with fixed or CPI-linked annual reviews | Dominant (precise split not publicly disclosed in reviewed sources) | | Outgoings recoveries | Recovery of operating costs from tenants | Not publicly disclosed | | Funds management income | Management and performance fees from third-party capital, including the Irongate Templewater Australia Fund (ITAP), following internalisation | Small (not publicly disclosed); the funds management business was sold to Charter Hall for A$5.0 million in 2022 | | Co-investment income | Distributions from co-investment stakes in managed funds (incl. ITAP) | Not publicly disclosed; co-investment stakes sold to Charter Hall for A$22.5 million | | Fair value gains | Non-cash property revaluations (drove the large statutory/headline earnings in FY2022) | Not a cash revenue line | The business was overwhelmingly a "landlord" model — the equivalent of a long-duration lease/annuity revenue model rather than product, subscription or licensing revenue. The distribution policy targeted a payout of 80%–100% of funds from operations (FFO), with the FY2022 payout expected in the middle of that range (Business Day, 5 May 2021). ### Value chain position Irongate sat at the asset ownership and active asset management layer of the commercial real estate value chain: acquiring assets (often off-market), leasing and repositioning them, managing capital structure, and, increasingly after 2020, managing third-party capital. It did not operate as a large-scale developer or construction business. ### Customer types and end-markets | Customer / end-market | Description | |---|---| | Office tenants | Corporate, government and professional-services occupiers in metropolitan and suburban office markets (e.g., Canberra — 24 Wormald Street, Symonston ACT, a government-leased asset; Cremorne, Melbourne; Wellington, NZ) | | Industrial tenants | Logistics, distribution, light manufacturing and trade occupiers in Brisbane, Perth, Sydney and Melbourne industrial precincts | | Capital customers (investors) | South African institutional and retail investors (JSE register), Australian institutions (ASX register) and third-party wholesale capital (ITAP and successor mandates) | ### Company's own description The company's own description (paraphrased from its investor materials as summarised by Simply Wall St, July 2022): Irongate traces its origins to Investec Group's Australian and New Zealand property investment and asset management business; having invested in and managed more than A$3 billion of assets for Investec, the long-standing management team evolved into Irongate Group to continue growing and to expand its third-party funds management platform. ### Independent characterisation Independently, Irongate is best understood as a mid-sized, value-oriented diversified REIT that used its JSE origins as a funding arbitrage (South African investors seeking Australian dollar yield) and then broadened its investor base via the ASX. Its strategic arc — internalise management, tilt toward industrial, build funds management — was coherent, but its sub-scale size (~A$1.7bn) relative to Australian sector leaders, a register concentrated in South Africa, and the low-rate environment of 2021–22 made it an obvious consolidation target. Post-2022, the "business" is a private, capital-light funds and asset manager whose economics depend on fee-earning AUM and co-investments with partners such as Burstone and TPG Angelo Gordon.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2013
Sydney, Australia
Ironbark

Ironbark Balanced Income Limited

Premium
Information Technology

**What it is:** Ironbark Balanced Income Limited is a small, closed-end Australian listed investment company (LIC) with roughly A$58m of net assets. It runs a multi-asset, income-first portfolio managed by Sam Kaplan's Kaplan Funds Management. **What it holds:** About half the book sits in floating-rate bank and insurer subordinated notes and hybrids. The rest is spread across: - property trusts; - utilities; - covered-call ("buy & write") positions in large-cap banks and resource stocks; - cash. **Track record:** The company has compounded at about 8.8% a year since 2003, including franking credits and before fees. Volatility has been roughly half that of the ASX. **Distribution model:** It distributes fully franked dividends, now paid quarterly. **2025 repositioning:** In late 2025 the company: - renamed itself to stress its income character; - moved from half-yearly to quarterly dividends; - reset its benchmark to RBA cash rate + 3% a year. **Strategic rationale:** The repositioning targets investors displaced by APRA's phase-out of ASX-listed bank hybrids by 2032. **Key structural features:** - a controlling 41.6% (registered) / 46.6% (substantial-holder notice) stake held by the manager's parent, Kaplan Partners; - a persistent 22–27% discount to NTA; - an active on-market buy-back. --- ### Company's own description **Principal activity:** AR26 describes this as investing in ASX-listed securities. Two outcomes follow from that activity: paying fully franked dividends and preserving capital [AR26 Directors' Report]. **Revenue sources:** Note 1 says the company invests in, and earns income from, listed securities, wholesale fixed interest securities and unit trusts in Australia [AR26 Note 1]. **Website description:** The website presents a balanced investment approach across ASX-listed and fixed income securities, aimed at an absolute return objective. Typical holdings include: - buy & write strategies; - property trusts; - utilities and infrastructure; - hybrids; - corporate bonds and fixed interest [WEB Home]. **Investment objective:** A return above RBA cash rate + 3% a year, with an emphasis on income and quarterly dividends [WEB Home]. ### Business model and revenue model IBC is not an operating company. Its "revenue" is total investment income from a trading portfolio carried at fair value through profit or loss. That income has two parts. 1. **Recurring income (A$3.09m in FY26) [AR26 Note 6]:** - interest on floating-rate notes and hybrids (A$1.24m); - franked and unfranked dividends (A$1.22m); - trust distributions (A$0.63m). 2. **Net gains on the trading portfolio (A$1.14m in FY26):** - realised gains/losses, including realised call-option premium, which was a A$0.82m net realised loss in FY26; - unrealised mark-to-market, which was a A$1.96m gain in FY26 [AR26 Note 6]. **Revenue mix in conventional terms.** - Product, service, subscription and licensing revenue are all zero. - About 73% of FY26 total investment income was recurring yield (3,091 / 4,230). - About 27% was net capital and option gains. - This split swings sharply from year to year. In FY23, gains were 54% of income; in FY22, net gains were negative [AR22; AR23]. **Cost base.** All costs are external. - Management fee of 0.60% a year of portfolio value, with no performance fee since 1 January 2024 [AR24; AR26]. - Accounting and secretarial fee to KFM. - Custody, registry, ASX, audit, directors' fees and D&O insurance. - FY26 total expenses were A$826k [AR26]. **Shareholder economics.** - Earnings are transferred to a Profit Reserve and paid out as fully franked dividends. - The Board's policy is to pay only fully franked dividends and to distribute the majority of franking credits received [AR26 Note 2(k)]. - The Dividend Reinvestment Plan has been suspended since 2008 [WEB Dividend History; AR26]. ### Value chain position | Role | Party | |---|---| | Investment management | KFM (Sam Kaplan CEO; Douglas Hew, Portfolio Manager for IBC) [WEB] | | Accounting and administration | KFM, under an Administrative Services Agreement effective 1 April 2014 [AR26] | | Custody | MUFG Corporate Markets FS [AR26] | | Registry and company secretarial | Boardroom [AR26] | | Audit | MNSA [AR26] | | Cash deposits | National Australia Bank (S&P AA-) [AR26 Note 8] | IBC is a capital pool, or "wrapper", at the end of the asset-management value chain. ### Customer types and end-markets **"Customers" are shareholders:** There were 1,389 holders at 29 July 2026, down from 1,558 in August 2022 [AR26; AR22]. **Concentration:** - Kaplan Partners Pty Limited holds 41.63% of registered shares. - Total relevant interest per the latest notice in AR26 is 46.63%. - The top 20 holders own 65.56%. - The remainder is mostly self-managed super funds, private investment companies and individuals [AR26 Shareholder Information]. **End-markets the portfolio invests in:** All Australian: - bank and insurer capital securities (Tier 1 and Tier 2); - corporate subordinated debt (Ampol, APA, Scentre); - large-cap banks and resources, accessed through covered calls; - REITs (healthcare, long-WALE, service-station); - utilities (Origin, APA); - an insurance broker (Steadfast) [AR26 Portfolio Shareholdings]. ### Independent characterisation **What IBC is in practice.** IBC is best understood as a sub-scale, manager-controlled, closed-end multi-asset income fund. Its edge is a disciplined absolute-return process with three parts: - holding floating-rate credit with low duration; - writing calls on equity exposures to monetise volatility; - keeping dry powder in cash and option delta. **Long-run outcome.** Since inception, the portfolio has returned 8.8% a year before fees with franking credits. It did so at around half the volatility of the ASX 300 [AR26 IM Report; WEB]. Over shorter periods, however, the record against benchmark is mixed: - underperformed the old benchmark (1-year swap + 6%) over 10 years, by 0.39% a year to June 2025 [AR25]; - beat the new, lower benchmark (RBA cash + 3%) in FY26 [AR26]. **Main commercial challenges:** **Scale:** About A$58m of net assets makes fixed costs heavy; the expense ratio was about 1.40% of average equity in FY26. **Discount to NTA:** Typically 22–27%. **Liquidity and governance perception:** A dominant manager-affiliated holder limits free float and constrains perceptions of independence. **The 2025 rebrand.** The rebrand was an attempt to re-rate the shares. It pitched IBC as a ready-made alternative for income investors leaving the closing listed bank-hybrid market [NC25; AGM25].

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1987
Sydney, Australia
iQ3Corp

iQ3Corp Ltd

Premium
Information Technology

| Field | Detail | Source | |---|---|---| | Legal name | iQ3Corp Ltd (Administrators Appointed) | Federal Court of Australia, [2022] FCA 397 (6 Apr 2022) | | Former names | None recorded | Market Index IQ3 profile | | ACN | 160 238 282 | FY2020 Annual Report cover; [2022] FCA 397 | | Incorporation year | 2012 | MarketBeat / Investing.com company profiles (aggregator); consistent with ACN series | | Incorporation jurisdiction | Australia (public company limited by shares, Corporations Act 2001 (Cth)) | FY2020 AR, Note 1 | | Registered office / HQ (last reported) | Level 9, 85 Castlereagh Street, Sydney NSW 2000 | FY2020 AR, Corporate Directory | | Share registry | Boardroom Pty Limited, Level 12, 225 George Street, Sydney NSW 2000 | FY2020 AR | | Exchange / ticker | ASX: IQ3 (listed 18 May 2015; suspended; removed 26 Aug 2022) | [2022] FCA 397; ASX Market Announcement 29 Aug 2022 | | ISIN | Not publicly disclosed in sources retrieved (AU-prefixed ISIN would have applied) | — | | CUSIP | Not applicable (no US listing) | — | | Fiscal year end | 30 June | FY2020 AR | | Employees | Not publicly disclosed. Proxy: employee benefits expense A$1.76m (FY2020) vs A$2.87m (FY2019) | FY2020 AR, Note 7 | | Auditor (last) | Vincents Audit Pty Ltd, Canberra (engagement director Phillip William Miller CA) | FY2020 AR, auditor's independence declaration | | Regulatory licence status | Corporate authorised representative of AFSL 451144 | FY2020 AR, Review of operations | | Shares on issue (30 Jun 2020) | 103,925,001 fully paid ordinary shares | FY2020 AR, Note 20 | | Market capitalisation (current) | Not applicable (delisted). Last quoted price A$0.12, implying about A$12.5m on 103.9m shares (historical, illiquid) | Investing.com historical data | | Market capitalisation at IPO | A$30.545m at A$0.30 per share | IPO close announcement, May 2015 | | Website | http://iq3corp.com (as supplied; www.iQ3Corp.com cited in FY2020 AR). | FY2020 AR | | External administrators | Mark Robinson, Riad Tayeh and Antony Resnick (joint and several) | [2022] FCA 397 | iQ3Corp Ltd was a micro-cap Australian corporate finance boutique that described itself as the world's first dedicated life science corporate finance and advisory firm. It provided capital raising, IPO and listing advisory, M&A, structured finance, restructuring and NSX nominated-adviser services to biotech, medtech and pharmaceutical companies in Australia and, through US subsidiaries, the United States. In practice it was a captive service provider inside the "iQ Group" of companies founded by Dr George Syrmalis. Its FY2020 accounts state that 100% of revenue came from related parties, and the group's administrators later described a web of intercompany loans and shared-labour arrangements. Revenue grew from A$2.1m (FY2016) to A$6.9m (FY2020), but losses widened, equity turned negative and the auditor flagged a going-concern material uncertainty. The group collapsed into voluntary administration in March 2022, and iQ3Corp was delisted from the ASX in August 2022. It is now a distressed-asset and governance case study rather than a going concern. --- ### Company's own description (FY2020 Annual Report) The FY2020 Directors' Report gives the principal activity as the provision of capital raising and corporate advisory services to listed and unlisted companies in the life science industry. The Review of Operations positions the company as a specialist corporate finance adviser to the life science sector. It describes expertise in mergers and acquisitions, strategic matters, restructuring and capital structure, and capital raising, offered to corporations, partnerships, institutions, governments and individuals. The FY2019 Annual Report called iQ3Corp the world's first dedicated life science corporate finance firm, under the tagline "Translating Science into Capital and Beyond". In FY2020 management said the company had advised boards and executives on the best business model for commercialising new life science intellectual property. That work covered market entry, funding, licensing and partnering strategies, and identifying counterparties in Australia and offshore. Management also cited new projects and collaborations with US business partners, which it expected to produce a pipeline of work over the following 12–24 months. Aggregator profiles (MarketBeat, Investing.com) add IPO and listing advisory, private equity, structured finance, sell-side and buy-side mandates, and NSX nominated-adviser services to the list. ### Business model and revenue model | Revenue stream | Model type | FY2020 (A$) | FY2019 (A$) | Share of FY2020 revenue | |---|---|---|---|---| | Capital raising and corporate advisory fees | Professional services: project/success fees, fixed price or hourly | 6,760,211 | 5,647,659 | 98.0% | | Office and shared services revenue | Cost-recovery / service fees charged to related entities | 139,757 | 513,190 | 2.0% | | Total | — | 6,899,968 | 6,160,849 | 100% | Source: FY2020 Annual Report, Notes 4 and 5. All revenue was recognised over time as services were rendered, on either a fixed price or an hourly rate (Note 5 accounting policy). There was no product, subscription or licensing revenue. The company did hold "licences" as an indefinite-life intangible asset (A$307,986 at 30 June 2020), but these generated no disclosed revenue. ### Independent characterisation On paper, iQ3Corp was an advisory boutique. Economically, it functioned as a related-party service vehicle. Three disclosures from FY2020 are decisive: 1. **Customer concentration of 100% to related parties.** Note 4 states that the Group's revenue came only from related parties. Note 30 confirms that all A$6.76m of advisory fees and all A$0.14m of shared-services fees were received from related parties. The related entities were The iQ Group Global Ltd (formerly iQnovate), iQX Limited, OncoTEX entities, Biosensx (North America) Pty Ltd and New Frontier Holdings LLC. 2. **Cash conversion was weak.** Related-party receivables were A$2.48m gross at 30 June 2020, against FY2020 revenue of A$6.90m, or roughly 126 days of revenue. 3. **Funding came from inside the group.** Liquidity relied on a A$927,000 bond from related party iQX (9% coupon, maturing 30 June 2022) and an undrawn A$3m iQX working capital facility, also at 9%. The going-concern basis rested on related-party capital-raising fees and related-party funding. The auditor's key audit matters were going concern, related party transactions, and recognition and impairment of intangibles. The audit report described a group of subsidiaries and companies with varying ownership levels, which transacted with one another and performed similar functions in different market sectors. The administrators' evidence to the Federal Court in April 2022 confirmed this picture. Entities in the iQ Group relied on each other for day-to-day funding. There were many intercompany loans, often written off or reclassified without adequate explanation, and loan balances were inconsistent between counterparties. Entities sometimes paid other entities' employees, and shared-labour arrangements were common. The administrators considered Farmaforce, not iQ3Corp, to be the group's principal operating company ([2022] FCA 397, paras 4–5). ### Value chain position | Value-chain stage | Activity | iQ3Corp role | |---|---|---| | Discovery / IP origination | University and research-institute IP, early-stage biotech | None directly; sourced via sister company iQ Group Global (IP asset manager) | | Corporatisation and structuring | Company formation, IP licensing, structuring | Advisory (stated FY2020 focus: "finding, funding, corporatising and capitalising early stage biotech assets", per Lei Xu biography) | | Capital raising | Seed, pre-IPO, IPO, secondary raisings | Core fee-earning service | | Listing / nominated adviser | ASX and NSX listings; NSX nominated adviser | Service offered (NSX nominated adviser per aggregator profiles) | | Investment / funds management | Bioscience funds | Sister company iQX Limited (NSX: IQX) | | Commercial execution | Pharma sales forces, medical affairs | Sister company Farmaforce Ltd (ASX: FFC) | iQ3Corp sat between life science asset originators and capital markets: ### Customer types and end-markets | Customer type | Evidence | Notes | |---|---|---| | Related-party life science companies | FY2020 AR Note 30: 100% of revenue | iQ Group Global, iQX, OncoTEX, Biosensx, New Frontier | | Listed and unlisted biotech/medtech | Stated target market | No disclosed third-party clients in FY2020 | | Governments, institutions, individuals | Stated in boilerplate | No disclosed revenue | | US life science companies | US subsidiaries (iQ Capital (USA) LLC etc.) | Revenue geographically disclosed as Australia only | End-markets: biotechnology, medical devices and diagnostics (notably saliva-based biosensors developed within the wider iQ Group), oncology (OncoTEX associate) and pharmaceutical services.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded2012
Sydney, Australia
IOUpay

IOUpay Limited

Premium
Information Technology

Ovanti Limited is an ASX-listed micro-cap fintech in deep distress and repeated strategic transition. Its only recurring commercial engine is iSentric Sdn Bhd, a Kuala Lumpur-based provider of mobile banking, authentication, digital payments and mobile-services infrastructure. iSentric has served Malaysian banks, telcos and corporates for about 20 years. Under the IOUpay name, the group built a Malaysian BNPL business (myIOU) in 2020–2022. That business collapsed after an alleged A$19M fraud by its former CFO, which led to a 2023 voluntary administration. Between 2024 and 2026 the reconstituted board pursued a US BNPL venture (Flote), a NASDAQ SPAC, a "financial super app," prediction markets and a BNPL relaunch. In August 2026 it abandoned BNPL entirely after the US subsidiary entered Chapter 7. The company now positions itself around iSentric plus "programmable financial rails" (supply-chain finance, CBDC, digital-asset exchange) across South-East, South and Central Asia. Its financial position is precarious: A$0.29M cash at 30 June 2026 against an FY2026 operating cash burn of A$21.1M. --- ### Company's own description Ovanti's standard ASX boilerplate (2025–2026 announcements) describes it as a provider of fintech and digital commerce software solutions and services. These let institutional customers securely authenticate end-user customers and process banking, purchase and payment transactions. Its core technology platform lets large customer communities connect with end users on any mobile device, and integrates mobile technology into existing products. The boilerplate names the divisions as Mobile Banking and Digital Payments, serving leading banks in Malaysia and large telcos and corporates in Malaysia and Indonesia. It adds mobile over-the-top (OTT) services delivered with telecommunication network providers. Until August 2026 the boilerplate also referred to global BNPL expansion as part of a "Super App" offering (Results of Meeting, 18 June 2026). ### Independent characterisation In economic substance, Ovanti in October 2026 is two things. 1. **A small Malaysian B2B mobile-services and payments-technology operator (iSentric).** It is the group's only revenue line. FY2026 statutory revenue from continuing operations was A$2.34M, all classified as "Mobile services," all recognised over time, and all from Malaysia (FY2026 4E Note 1). Management's 20 August 2026 announcement cited about A$3.58M of FY2026 iSentric revenue. That figure does not reconcile to the statutory A$2.34M, and the difference was unexplained in the sources reviewed. 2. **A holding vehicle for a 21% equity-accounted stake in I-Destinasi Sdn Bhd (IDSB), a Malaysian finance company.** The stake is carried at A$14.31M, about 89% of total assets of A$16.02M at 30 June 2026. It contributed A$1.44M share of profit in FY2026 (A$1.79M in FY2025) and paid A$0.28M in dividends (A$1.17M in FY2025). The company has tried to sell this stake since 2024 without a completed sale being verified. Everything else is pre-revenue or proof-of-concept: the August 2026 "programmable rails" strategy (JuncturaX supply-chain finance, a Nepal CBDC proof-of-concept, a Tajikistan digital-asset exchange pilot, OmiCloud), the Ominari prediction-market platform, and the Yuno.trade partnership. The US BNPL business (Ovanti US Inc / Flote) is discontinued and in Chapter 7. It contributed a A$3.86M loss in FY2026. ### Value-chain position, customers and end-markets iSentric sits in the middle layer between telco networks and financial institutions. It provides the messaging, authentication and transaction-processing middleware that banks and corporates use to reach and verify mobile end users. Disclosed customer types are banks (one report cites Standard Chartered Bank as a client of the regional banking relationships, Grafa, June 2026), insurers, telcos and large corporates in Malaysia and Indonesia. Earlier IOUpay materials said it served about 20 of Malaysia's leading banks, insurers and telcos (FinTech Futures, April 2023). End-markets are Malaysian retail banking, telecommunications and enterprise digital engagement.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded2000
Melbourne, Australia
Invion

Invion Limited

Premium
Information Technology

Invion Limited is a Melbourne-based, micro-capitalisation clinical-stage life-sciences company developing Photosoft™, a next-generation photodynamic therapy (NGPDT) platform comprising a library of more than 300 photosensitiser compounds. Its lead candidate, INV043, is a light-activated photosensitiser being studied in topical, sublingual and intravenous forms across non-melanoma skin cancer, anogenital cancers, prostate and oesophageal cancer, with theranostic potential (therapeutic activation under 660nm red light and diagnostic fluorescence under 405nm violet light). In December 2025 Invion converted a patchwork of territory-limited licences from the technology's inventor group (RMW Cho Group) into a perpetual, exclusive global licence for a portfolio of "Agreed Indications" across human and animal health, paid in milestone-linked shares and royalties. The company operates a capital-light, partner-funded model — Hanlim Pharm (oesophageal, supported by a Korean government grant), SANGMYUNG Innovation (wet AMD) and Protect Animal Health (companion animal oncology) — but faces acute funding constraints, with A$0.59M cash at 30 June 2026 and a going-concern emphasis from its auditor. --- ### Company's own description (paraphrased from FY2026 Annual Report) In its FY2026 Directors' Report, Invion describes itself as a clinical-stage life-science company leading the global research and development of Photosoft™ technology for treating a range of cancers and infectious diseases in both human and animal health. It holds an expanded, perpetual and exclusive global licence to Photosoft™ carrying rights to develop, manufacture, market, distribute, sub-license and otherwise commercialise the technology for a defined portfolio of "Agreed Indications". The company states it partners with research institutes, notably the Peter MacCallum Cancer Centre (Peter Mac) and the Hudson Institute of Medical Research, to develop a novel photosensitiser intended to improve treatment of skin cancers and hard-to-treat solid tumours, with the aim of more effective targeting and killing of cancer cells with fewer side effects and minimal discomfort. ### Independent characterisation | Period | Model | Revenue source | |---|---|---| | FY2018–FY2024 | Contract R&D service provider to the technology owner: RMWCG funded Photosoft™ cancer R&D in Australia/NZ under a 31 Aug 2017 R&D Services Agreement, with revenue recognised on a fully-burdened cost basis | R&D services fees from RMWCG (A$3.29M FY2022; A$4.10M FY2023; A$3.69M FY2024) | | FY2025 | Transitional; RMWCG stopped settling invoices; ~A$4.07M receivable fully provided | Nil revenue | | FY2026 onward | Global licensee and platform out-licensor; partner-funded preclinical work; future royalties/sub-licensing | Non-clinical research funding from Hanlim Pharm (A$384,707 in FY2026) | Invion is, in substance, a virtual biotech and IP-licensing vehicle. It owns no laboratories or manufacturing plants; R&D is executed through contract research organisations, clinical sites (Veracity Clinical Research and Cornerstone Dermatology in Queensland), academic partners (Peter Mac, Hudson Institute, University of Adelaide's ACARE) and outsourced chemistry/manufacturing providers. Its core asset is a licence (carried at A$7.46M on the balance sheet at 30 June 2026) to a photosensitiser library invented by Michael Honsue Cho, controller of RMW Cho Group Limited (RMWCG) and the newly formed licensor entity NGPDT IP (Holdings) Pty Ltd. **Business model evolution:** **Revenue model mix (FY2026):** 100% contract research/service funding from one customer (Hanlim Pharm Co., Ltd, South Korea). Product revenue: nil. Licensing/royalty income: nil to date. Subscription: not applicable. **Value chain position:** Upstream drug discovery and early clinical development (preclinical to Phase I/II). Invion's strategy contemplates sub-licensing to pharmaceutical partners for late-stage development and commercialisation; under the prior territory licences a 50% sub-licence fee share was payable to RMWCG, while the new global licence provides for royalties on future net sales and certain sub-licensing or analogous payments (exact rates not publicly disclosed in the sources reviewed). **Customer types:** (i) pharmaceutical and biotech partners (Hanlim Pharm, SANGMYUNG Innovation, Dr. I&B Co., Ltd., Protect Animal Health Inc.); (ii) historically, the technology licensor (RMWCG) as R&D services customer. Ultimately, end-users would be dermatologists, oncologists, ophthalmologists and veterinarians. **End-markets targeted:** Non-melanoma skin cancer (SCC, BCC); anogenital cancers (anal, vulvar, penile); oesophageal cancer; prostate cancer; glioblastoma multiforme; HPV-related disease; wet age-related macular degeneration; companion-animal oncology; infectious diseases (antimicrobial-resistant bacteria, fungi, viruses); atherosclerosis; periodontal disease.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded2000
Melbourne, Australia
Invictus

Invictus Energy Limited

Premium
Information Technology

Invictus Energy is an Australian-domiciled, Zimbabwe-focused upstream oil and gas explorer that has staked a basin-master position over one of the last large untested onshore rift basins in Africa – the Cabora Bassa Basin in the Muzarabani district of northern Zimbabwe. Through its 80%-owned operating subsidiary Geo Associates, the company holds approximately 360,000 hectares (3,600 km²) across Special Grant 4571 and Exclusive Prospecting Orders 1848 and 1849. Its Mukuyu gas-condensate discovery (Mukuyu-1 in 2022, confirmed by Mukuyu-2 in late 2023) was ranked by Wood Mackenzie as Sub-Saharan Africa's second-largest oil and gas discovery of 2023. Invictus now holds a signed Petroleum Production Sharing Agreement (May 2026), National Project Status and Special Economic Zone benefits, and is preparing to spud the Musuma-1 exploration well in November 2026. The equity story is a binary, catalyst-driven frontier exploration play targeting a gas-starved Southern African market, with financing risk as the principal constraint. --- ### Company's own description In its ASX announcement boilerplate and annual reports, Invictus describes itself as an independent upstream oil and gas company focused on high-impact energy resources in sub-Saharan Africa, with a highly prospective 360,000-hectare position in the Cabora Bassa Basin containing the Mukuyu gas field and multiple Basin Margin prospects. Since early 2024 it has described itself as transitioning "from explorer to developer" following the Mukuyu discovery, and states a commitment to operating safely, ethically and responsibly with respect for host communities. ### Independent characterisation Invictus is a single-asset, pre-revenue frontier explorer. Its value lies almost entirely in (a) the capitalised exploration and evaluation (E&E) asset of A$131.4 million at 30 June 2026, (b) the regulatory and fiscal framework it has negotiated with the Government of Zimbabwe, and (c) the option value of untested prospects across the basin. It has no producing assets, no operating revenue, no debt facilities and no dividend capacity. It funds itself by repeated equity placements and rights issues on the ASX and VFEX, and has previously sought a strategic cornerstone investor (the failed Al Mansour Holdings transaction). ### Business model and revenue model | Dimension | Characterisation | |---|---| | Business model | Frontier exploration → appraisal → staged development; monetise through domestic gas sales, gas-to-power, condensate sales, and potentially farm-down of equity to a larger partner | | Current revenue | Nil operating revenue; minor interest/other income (IBISWorld estimates total FY2025 income ≈ A$0.19M) | | Product mix (future) | Natural gas (pipeline/CNG/gas-to-power), condensate/light oil, potential carbon credits (REDD+ project) | | Service / subscription / licensing revenue | Not applicable | | Value-chain position | Upstream (licence holder and operator). No midstream or downstream assets | | Prospective customer types | Industrial gas users (ammonium nitrate fertiliser – Sable Chemicals), independent power producers (Tatanga Energy, Mbuyu Energy), mines (Eureka Gold Mine via Dallaglio/Himoinsa gas-to-power), and potentially regional export markets | | End-markets | Zimbabwe domestic energy (power deficit, imported fuels and fertiliser feedstock); Southern African gas market | ### Commercialisation pathway (as disclosed) Company presentations (April and September 2026) describe a sequenced plan: (1) Musuma-1 exploration to test a new play type in the eastern Cabora Bassa; (2) Mukuyu appraisal including a Mukuyu-3 well, 3D seismic and well testing to establish commerciality; (3) Phase 1 pilot gas-to-power supply to the Eureka Gold Mine (approximately 50 km south of Mukuyu), which already has environmental approval, to generate early cash flow and reservoir data; (4) larger-scale development of a Cabora Bassa gas-condensate project, funded by some combination of debt, equity and a senior farm-in partner.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2011
West Perth, Australia
Interagro

Interagro (UK) Ltd

Premium
Information Technology

Interagro (UK) Limited was a British specialist formulator and marketer of in-can agricultural adjuvants and plant biostimulants, founded by Mike Roche and trading since 1994. These products are not pesticides themselves. They are spray-tank additives and plant-health inputs that make crop protection chemistry work better: water conditioners, pH buffers, compatibility agents, drift retardants, activator oils and spreaders, pod sealants, soil conditioners and stabilisers, and amino-acid, peptide and seaweed biostimulants. Its flagship brands, Kantor, Toil, Backrow, Spur, Sorrento, Newton and Bridgeway, built a reputation with UK agronomists. Out-licensing through distributors such as Cérience in France took its products to 27 country markets. In April 2023 Japan's Nihon Nohyaku bought the company through Nichino Europe, its first acquisition in Europe, to move beyond synthetic agrochemicals. From April 2025 the business operated as part of Nichino Europe. The legal entity entered solvent liquidation in December 2025, while its portfolio now acts as Nichino's direct-to-market platform in the UK and Ireland. --- ### Company's own description Interagro's legacy website describes the company as a results-driven adjuvant and biostimulant business. It says the company aims to improve the performance of crop protection inputs and improve plant health. The range covers adjuvants, water conditioners, soil care and anti-drift agents, plus biostimulants intended to reduce abiotic stress so crops can reach their genetic yield potential (interagro.co.uk, accessed Oct 2026). At acquisition, Nichino described Interagro as a leading manufacturer of in-can adjuvants and biostimulants operating in 27 countries. It said the full portfolio covered water conditioners, pod stickers, specialist anti-drift agents, and foliar and seed-treatment biostimulants (Nichino Europe release, 3 April 2023). No annual-report "business description" was retrieved. The strategic report in the filed group accounts would contain one but was not accessible. ### Independent characterisation **Business model.** Interagro was an asset-light, IP- and registration-led specialty formulator. Its value came from four things: - Proprietary formulations and trademarks. For example, Cérience's French label for Cantor/Pentra names the products as registered trademarks and property of Interagro UK Ltd. - Regulatory approvals. Adjuvants in the UK need Chemicals Regulation Division (CRD) approval, and in France an AMM (e.g., AMM no. 2090013 for Cantor/Pentra, an ethoxylated soybean oil EC at 790 g/L). - Field-trial evidence, including University of Nottingham glasshouse work in 2022 on Newton and Bridgeway. - Agronomist-facing technical marketing. The SIC code is "manufacture of other chemical products". However, the 2023 headcount of 13 people strongly suggests manufacturing was toll-formulated by third parties rather than run in owned plants. This is an inference, not a disclosed fact. **Revenue model.** Revenue was almost entirely product sales, in two channels: 1. UK distribution through agricultural merchants and distributors, with demand created by agronomists. 2. International out-licensing and supply of branded or private-label products to crop protection manufacturers, co-operatives and distributors. The international page notes the same products are sold under different trade names in different markets. For example, the pod sealant Iskay is also sold as Flexi, Latiss or Vice, and the Kantor formulation appears in France as Cantor/Pentra via Cérience. There is no evidence of subscription, service or licensing-fee revenue. A royalty or brand-licence element in out-licensing deals is possible but not disclosed. **Value-chain position.** The company sat between commodity surfactant and oil suppliers upstream and distributors and agronomists downstream. Its added value lay in formulation, registration, claims support and brand. **Customers.** Its direct customers were distributors, merchants, co-operatives and crop protection manufacturers. End users were arable farmers (cereals, oilseed rape, pulses), potato growers, horticulture and fruit producers, and organic growers (Bridgeway carries Soil Association and Organic Farmers & Growers certification). **End-markets.** Agricultural adjuvants and biostimulants in the UK, the EU (notably France and the Netherlands), Eastern Europe, North Africa and the Middle East. **Post-2023 role.** Within Nichino, Interagro gave the group a route to market in the UK and Ireland. From January 2025 Nichino began selling its own pyraflufen-ethyl products (GOZAI, KABUKI) through the Interagro platform, with flutolanil-based products following in summer 2025 (Nichino Europe press release, 2025). The business therefore changed from a stand-alone adjuvant house into the commercial front end of a Japanese research-based agrochemical company in Britain and Ireland.

Revenue$0.7B
Employees11
Market CapN/A
Founded1994
United States, North America
Intelicare

Intelicare Holdings Limited

Premium
Information Technology

InteliCare is a Perth-based software-as-a-service company. It commercialises a proprietary, AI-driven Internet-of-Things care platform for Australian residential aged care, retirement living, disability and health providers. The platform combines ambient sensors, vital-sign and bed-occupancy monitoring, falls detection, real-time location tracking, staff duress and, since 2026, a proprietary nurse call layer, all in one clinical dashboard. Its purpose is to improve resident safety, reduce manual welfare checks and support compliance under Australia's new aged care regulatory regime. After six years of pilots, sub-scale revenue and repeated equity raisings, the company reached its first commercial inflection in FY2026. It signed a five-year, roughly A$8.8 million Master Subscription Agreement with mecwacare covering 22 facilities and about 1,600 beds. It expanded its Hardi Aged Care contract, entered retirement living through Warrigal, more than doubled sales revenue, and recorded its first positive operating cash flow quarter since listing. It remains loss-making, highly concentrated by customer and heavily dilutive. --- ### Company's own description In its FY2026 Directors' Report, InteliCare describes its principal activities as three items: production of a predictive analytics solution for care providers in aged care, disability and healthcare; sales and marketing; and research and development. ASX announcements in 2026 describe it as an Australian SaaS technology company commercialising its AI-driven InteliCare platform across the aged care, disability and health sectors. The longer boilerplate in its releases says it uses smart sensors and AI on a proprietary IoT platform to help people stay in their own homes for longer, while helping providers deliver better and more efficient care. The FY2026 report describes the year as a transition from validating pilots to deploying at scale. The company focused on converting pilots into long-term contracts, carrying out deployments with leading aged care providers, building recurring SaaS revenue and improving the platform for larger, cheaper rollouts. ### Independent characterisation InteliCare is in practice a hardware-led, SaaS-tailed solution vendor to institutional aged care operators. Its value proposition has three parts: 1. **Clinical safety.** It detects falls, bed exits and changes in vital signs or behaviour patterns, and raises alerts. 2. **Workforce productivity.** It replaces manual overnight welfare rounds. In the mecwacare Trescowthick pilot, residents needing three-hourly overnight checks fell from 55 to 4. 3. **Compliance and governance.** It automates falls reporting, keeps audit trails and analyses alarm response times, which supports alignment with the new Aged Care Act and the strengthened Aged Care Quality Standards. The company began in 2020 with a home-monitoring and B2C/B2B home care model. Its products then were InteliCare Home and InteliLiving, funded through Home Care Packages and NDIS plans. Since about 2022–2023 it has pivoted firmly toward residential aged care. The 2026 launch of a proprietary nurse call solution marks a further move. InteliCare is no longer only an analytics overlay. It is starting to compete for, or displace parts of, the core clinical communications layer of an aged care facility. That brings it into direct competition with established nurse call vendors. ### Revenue model | Revenue stream | Description | Recognition | FY2025 (A$) | FY2026 (A$) | FY2026 mix | |---|---|---|---|---|---| | Hardware sales (incl. bundled implementation) | Sensors, hubs, gateways, nurse call hardware, plus implementation services bundled where not distinct | Point in time (on delivery) | 847,025 | 1,845,029 | 90.4% | | Subscription (SaaS) | Platform subscription fees per bed, site or residence | Over time | 109,715 | 196,799 | 9.6% | | Professional services | Referenced in mecwacare contract terms; not separately reported | Not separately disclosed | n/d | n/d | — | | Total sales revenue | — | — | 956,740 | 2,041,828 | 100% | *Source: FY2026 Financial Report, Note 5.* Other income outside sales revenue consists of the R&D tax incentive refund (A$610,680 in FY2026; A$619,528 in FY2025) and interest income. This income is material: in FY2026 it equalled about 30% of sales revenue. Commercial contracts are structured as multi-year Master Subscription Agreements. Each facility has its own order form, with up-front hardware and implementation fees followed by recurring SaaS. In the June 2026 quarter, hardware fees made up about 69% of cash receipts (Kalkine summary of the June 2026 Quarter Update). The share of recurring revenue is still small, but it is growing: SaaS revenue rose 79.4% year on year in FY2026. ### Value chain position, customer types and end-markets | End-market | Status | Named customers / counterparties | |---|---|---| | Residential aged care (RAC) | Core market; most revenue in FY2025–FY2026 | mecwacare (VIC), Hardi Aged Care (NSW) | | Retirement living | Entered FY2026 (first commercial deployment) | Warrigal Care (NSW/ACT) | | Regional / public health | Ongoing subscription | WA Country Health Service (WACHS), Koolberrin Lodge, Narembeen | | Home care / disability | Original market (2020–2022); now secondary | Historical: WA Department of Communities, Swan Care, Echo Community Services, Like Our Own | | Hospital / remote patient monitoring | Pilot stage | Peter MacCallum Cancer Centre pilot (concluded early 2024) | InteliCare designs the software, analytics and AI layer and specifies the sensor and hardware stack. Hardware is purchased and resold; hardware expense was A$882,227 in FY2026. Manufacturing arrangements are not publicly disclosed. The company handles implementation itself. All FY2026 external revenue came from sales to Australian aged care providers (FY2026 Financial Report, Note 4).

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2016
Leederville, Australia
Insumos

Insumos Agroquimicos S.A.

Premium
Information Technology

InsuAgro is a mid-sized, asset-light Argentine marketer and distributor of crop-protection and crop-nutrition products, founded in 2002 and controlled since April 2021 by Bioceres Crop Solutions Corp. It sells a broad, largely off-patent portfolio — herbicides, insecticides, fungicides, seed treatments, adjuvants, water correctors, growth regulators, plant-nutrition and biostimulation products — exclusively through agricultural retailers, organised into eleven sales zones each led by a senior agronomist. Its addressable crops span soybean, corn, wheat, sunflower, potato, beans, peanut, pastures and tobacco. Revenue reached ARS 41.1 billion in FY2026, but the business has slipped into operating losses for two consecutive years, carries net debt of ARS 25.4 billion against equity of ARS 6.1 billion, and received a going-concern qualification on its FY2025 accounts. Its strategic future is tightly bound to the restructuring of the Bioceres group, whose founding holding company was declared bankrupt in March 2026. --- **What the company does.** InsuAgro sources formulated agrochemicals and nutrition products from manufacturers and toll formulators — historically disclosed principal suppliers include FMC Química, Cheminova (now part of FMC), Borches y Cía and Rainbow Agrosciences (MAV, Fideicomiso Financiero Insuagro VI presentation, 2020) — and markets them under its own brands to Argentine farm-input retailers. Some descriptions of the business refer to "production" as well as distribution (Fintel; TradingView); the balance sheet shows modest property, plant and equipment (ARS 2,291M at FY2026, including land ARS 663M, buildings ARS 1,677M and machinery ARS 1,201M at gross values per S&P), which is consistent with warehousing and possibly light formulation or repackaging rather than active-ingredient synthesis. The company's own characterisation, used in its securitisation marketing materials, is that of a "comercializadora de insumos agropecuarios" (agricultural inputs trading company) with presence in all of Argentina's farming regions (MAV, Insuagro XII presentation). **Company's own description (paraphrased from its trust-programme presentations and website).** InsuAgro describes itself as a company created in 2002 that markets agricultural inputs nationwide, whose wide product range gives it access to the soybean, corn, wheat, sunflower, potato, bean, peanut, pasture and tobacco markets; it sells exclusively to retail outlets through eleven sales zones, each overseen by an experienced agronomist acting as zonal supervisor; it highlights a complete product line, very low geographic and customer concentration, a professional sales force that builds customer loyalty, and agility derived from limited investment in fixed assets. Since 2021 it presents itself as part of the Argentine Bioceres group (MAV, Insuagro XII presentation; company website). **Business model and revenue model.** Revenue is essentially 100% product sales (no material service, subscription or licensing revenue is disclosed). S&P's segment data splits revenue into Crop Protection (75.8% of FY2026 revenue) and Crop Nutrition (24.2%). The model is a classic "distributor-formulator" spread business: buy generic molecules on supplier credit (often USD-denominated), brand and position them, and sell on seasonal credit terms to retailers, financing the receivables gap through bank debt, negotiable obligations, and — distinctively — public-offering financial trusts that securitise trade receivables (Fideicomisos Financieros "Insuagro" series). InsuAgro acts as trustor (fiduciante), servicer and collection agent for these trusts, retains the participation certificates, and has agreed to replace defaulted receivables (BIOX 20-F FY2021, Note on Insuagro acquisition). **Value-chain position.** Downstream of global and Chinese/Indian active-ingredient manufacturers and formulators, upstream of retailers ("agronomías", cooperatives, distributors) who in turn sell to farmers. InsuAgro does not appear to own molecule IP; its value-add lies in registration management (SENASA product registrations), branding, agronomic advice and credit provision. **Customer types.** Agricultural input retailers and distributors only (no direct farmer sales are disclosed). Customer concentration is described as very low (MAV presentations); no customer above 10% of revenue is disclosed. **End-markets.** Argentine extensive crops (soy, corn, wheat, sunflower), regional/specialty crops (potato, beans, peanut, tobacco) and pastures. Geographic coverage includes the northwest, northeast and central farming regions (Fintel profile) — effectively the whole Argentine grain belt. **Independent characterisation.** InsuAgro is a sub-scale generic agrochemical brand-owner whose economics are driven less by product innovation than by working-capital management in a high-inflation, devaluation-prone, credit-intensive market. In FY2022 it earned an 11% EBIT margin; by FY2025–FY2026 the same gross margin structure (22–23%) no longer covered a sharply higher SG&A base (SG&A ≈ 24% of revenue), and financial costs, FX losses and bad-debt provisions (ARS 1,069M in FY2026) pushed it into net losses. Its strategic value inside the Bioceres group was as a distribution channel and as an additional crop-protection catalogue alongside sister company Rizobacter; that rationale is now subordinate to group liquidity.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2002
Ciudad Autónoma de Buenos Aires, Argentina
Instituto

Instituto Rosenbusch S.A.

Premium
Information Technology

Instituto Rosenbusch is a century-old Argentine animal-health laboratory. It develops, manufactures and sells veterinary biologicals (vaccines for cattle, sheep, goats, horses, dogs and cats) and pharmaceuticals (antiparasitics, endectocides, antibiotics, antimastitics, vitamins and minerals). Products are sold mainly to the Argentine livestock sector through a veterinarian-led commercial model, with exports to more than 50 markets. It is the only veterinary biologicals manufacturer listed on the Buenos Aires exchange. The company is in deep financial distress. It went through a concurso preventivo (court-supervised reorganisation) opened in November 2019. It reported a negative gross margin and negative equity at end-2025. In February 2026 control passed from the founding Balestrini family and associated holding companies to Agro 2000 S.A., a Córdoba-origin agribusiness supplier. The new controller is executing a balance-sheet repair (ARS 1.94 bn debt forgiveness plus an ARS 12.3 bn asset revaluation). The investment case now rests on operational turnaround under new ownership rather than on historical franchise strength. --- ### What the company does Rosenbusch is a vertically integrated veterinary products manufacturer. It owns its product registrations, runs in-house production of both bacterial/viral biologicals and pharmaceutical formulations at its Buenos Aires facility, and sells through its own commercial organisation. Data-vendor descriptions derived from the company's filings divide the portfolio into Biological Products (vaccines for the reproductive-respiratory complex, IBR, BVD, brucellosis, anthrax/carbunclo, clostridial diseases, pneumonia, calf diarrhoea and infectious bovine keratoconjunctivitis; vaccines for sheep, goats, horses and dogs) and Pharmaceutical Products (external and internal antiparasitics, endectocides, antimycotics/bacteriostatics, injectable antibiotics, antimastitics, other chemotherapeutics, vitamins and minerals), plus an Others line ([SA], [TV]). In addition, the company: - markets biolarvicides for environmental control of disease-carrying mosquitoes (dengue, malaria vectors) as an alternative to chemical fumigation ([BdC], [BW]); - has developed probiotics aimed at improving bovine gut health and lowering methane emissions ([BdC]); - offers specialised diagnostic services ([BdC]); - historically was also involved in slaughtering and meat products, according to an older data-vendor profile. Whether that activity continues is not publicly disclosed ([INV]). ### Business and revenue model | Dimension | Characterisation | Evidence | |---|---|---| | Revenue model | Almost entirely product sales (manufactured goods). Service revenue (diagnostics) is not separately disclosed and is believed to be immaterial. No subscription or licensing revenue disclosed. | [SA], [BdC] | | Product mix FY2025 | Pharmaceuticals 55.9%, Biologicals 41.1%, Others ~3.0% of sales | Company FY2025 annual report as summarised in [RAVA] | | Product mix 9M 2024 (local market) | Pharmaceuticals 43.13%, Biologicals 54.76% | [BdC] | | Market mix FY2025 | Domestic 68.8%, exports ~31.2% | [RAVA] | | Channel | Commercial model built on veterinarians based throughout Argentina. The founder believed only veterinarians should sell veterinary products. | [BdC], [RAVA] profile | | Value-chain position | Upstream manufacturer (R&D, registration, production). Sells to distributors, veterinary practices and producers. Competes with multinational and domestic originators and generic formulators. | Analyst assessment | | Customer types | Cattle ranchers and feedlots (beef and dairy), sheep/goat producers, equine owners, companion-animal veterinary clinics, public-health and municipal vector-control programmes (biolarvicides), export distributors | [BdC], [IC], [BW] | | End-markets | Argentine livestock health (core); companion animals; vector control; export markets (Latin America, Middle East incl. Libya, Oman, Dubai) | [BdC] | ### Company self-description The company describes itself, through its long-standing exchange profile, as dedicated exclusively to animal health, run by the third generation of the founding family, with a commercial model built on veterinarians across the country. It also claims a place among Argentina's 300 most important companies and leadership in many market segments, and stresses that it is the only company in its sector listed on the Buenos Aires exchange ([RAVA] profile text). That profile predates the February 2026 change of control. The "third generation of the family" statement is no longer accurate. ### Independent characterisation Analytically, Rosenbusch is a sub-scale, distressed domestic animal-health manufacturer with a heritage brand. Its strengths lie in clostridial, reproductive and anthrax (carbunclo) biologicals, where local registrations, cold-chain distribution and veterinarian relationships matter. In FY2025 it was squeezed between: - multinationals (Zoetis, MSD Animal Health, Boehringer Ingelheim, Elanco, Ceva) with far larger R&D budgets; and - well-capitalised national laboratories (Biogénesis Bagó, CDV, Over, König, Holliday-Scott). Revenue at FY2025 levels (≈ ARS 6.4 bn, roughly USD 4–5 M) makes it a micro-cap. Its economics are dominated by working-capital financing costs, FX exposure on imported inputs, and the Argentine inflation/devaluation cycle. The FY2025 collapse in biological sales (−61.4% in pesos) suggests that funding constraints impaired production and supply, rather than a pure demand shock. Management's own commentary cited lack of access to working-capital credit.

RevenueN/A
Employees72
Market Cap$0.0B
Founded1917
United States, North America
Ingenia

Ingenia Communities Group

Premium
Information Technology

Ingenia Communities Group is one of Australia's largest listed owner-operators and developers of affordable, community-based housing and holiday accommodation. Its core is the land lease ("lifestyle") community model for over-50s downsizers. In that model, residents buy a manufactured home and lease the land under it, which gives Ingenia two income streams: a one-off development margin on the home sale and a permanent, CPI-linked site-rent annuity. Three further pillars sit around this core. Ingenia Rental provides all-age rental communities. Ingenia Gardens is a seniors' rental village portfolio. Ingenia Holidays is a coastal holiday-park business spanning NSW, Queensland and Victoria. The FY26 property portfolio was about $2.7 billion or more across roughly 100 communities, with a land lease pipeline of about 8,800 sites. Under CEO John Carfi's 5-Year Plan (August 2024), Ingenia has shifted from serial acquirer to disciplined operator and developer. It is now attempting a transformational step into master-planned communities through the Peet acquisition, while fielding a private-equity take-private approach. --- ### Company self-description Ingenia's ASX releases describe the Group as a leading operator, owner and developer of communities that offer quality, affordable land lease, rental and holiday accommodation. The communities are organised under four brands: Ingenia Lifestyle, Ingenia Gardens, Ingenia Holidays and Ingenia Rental. The FY26 Results Presentation (25 August 2026) states that the Group has 104 communities and development sites. Releases issued after the September 2026 asset sales cite 96 communities and development sites. ### Business model Ingenia's economic engine has three interlocking parts. 1. **Land lease development (Ingenia Lifestyle Development).** Ingenia acquires greenfield or brownfield land, obtains approvals, installs civil works, and builds and sells manufactured homes, typically to over-50s downsizers. The FY26 average sale price was $681,000 including GST. FY26 gross development margin was about 48%, per the Quartr summary of the FY26 results. Once a home settles, the site moves into the rental annuity base. 2. **Recurring rental (Ingenia Lifestyle Rental, Ingenia Rental, Ingenia Gardens).** Land lease site rents are typically CPI-linked or subject to market review. All-age rental homes and seniors' rental villages add weekly rent. FY23 materials disclosed more than $2 million of rent collected weekly across these portfolios. 3. **Tourism (Ingenia Holidays).** Coastal holiday parks generate revenue from cabins, powered and unpowered sites and ancillary services. In some locations they also host permanent residents ("mixed-use" parks). FY26 Holidays EBIT was $63.2m, up 9%. A fourth component was a capital partnering and funds management business. It comprised the Eighth Gate funds acquired in 2019 and the development joint venture with Sun Communities (NYSE: SUI). The managed funds were wound up in FY25. The Sun JV continues and contributed 177 of the 573 FY26 settlements. ### Revenue model mix | Revenue type (analyst mapping) | Ingenia source | Character | |---|---|---| | "Product" sales | New manufactured home sales (Lifestyle Development) | Cyclical, volume × price; recognised on settlement | | "Subscription-like" recurring rent | Land lease site fees, Ingenia Rental, Ingenia Gardens | Annuity; CPI-linked or market reviewed; occupancy 94–99% | | Service / tourism | Ingenia Holidays cabins and sites, ancillary F&B and fuel | Seasonal, rate × occupancy; exposed to domestic tourism | | Fees | Deferred Management Fees (legacy, written off FY25); historical funds and asset management fees (exited FY25); JV performance fees | Minor | Ingenia does not report revenue on a "product/service/subscription/licensing" basis. Mapped to that framework, the mix looks like this. Morningstar estimates that about 70% of Ingenia's mid-cycle EBITDA comes from land lease property sales and rent (Morningstar note, September 2026). ### Value-chain position Ingenia is vertically integrated across land acquisition, planning, civil works, home design and procurement, sales and marketing, community management and holiday-park operation. Management has emphasised design and procurement efficiencies under the 5-Year Plan, including clubhouse rationalisation in new communities. ### Customer types and end-markets The four customer groups are: - **Over-50s downsizers**, mainly retirees and pre-retirees in coastal and regional NSW, Queensland and Victoria, buying land lease homes. Queensland is the largest land lease market. **All-age renters:** seeking affordable rental housing (Ingenia Rental). **Independent seniors on pensions:** in rental villages (Ingenia Gardens). - **Domestic leisure travellers**, families and grey nomads (Ingenia Holidays). ### Independent characterisation Ingenia is best understood as a hybrid. It is part residential real-estate investment trust, part housing developer and part tourism operator. This hybrid nature is both its strength (diversified, partly annuity cash flows) and its valuation problem (a conglomerate discount, plus development earnings that the market capitalises at a lower multiple than rent). The proposed Peet acquisition would shift the mix materially towards development. Pro forma, Ingenia would control a master-planned-community lot bank of about 26,400 lots. Warburg Pincus appears to want the existing, more annuity-weighted business instead.

Revenue$0.4B
EmployeesN/A
Market CapN/A
Founded2004
Sydney, Australia
Infinity

Infinity Metals Limited

Premium
Information Technology

Infinity Metals is an Australian micro-capitalisation mineral exploration company in the middle of a forced strategic reset. For roughly eight years it was a single-asset lithium developer, holding a 75% interest (via the Tecnología Extremeña del Litio joint venture with Sacyr's former mining arm) in the San José hard-rock lithium project near Cáceres in Extremadura, Spain — described by the company as hosting the EU's second-largest hard-rock lithium resource (c. 111 Mt at 0.61% Li2O). After years of permitting disputes, the return of an €18.8M Spanish PERTE grant, a full A$20.3M impairment in FY2025, and the regional government's rejection of its mining licence application in August 2026, management has pivoted toward lower-sovereign-risk exploration: an option over the historic high-grade Swansea copper mine (Arizona), an option over the Tule Canyon molybdenum-copper porphyry (Nevada), the 100%-owned Yambacoona tin project (NSW), and gold-silver-copper licences in eastern Victoria. It is pre-revenue, debt-free and funded by equity. --- ### Company's own description The FY2026 Annual Report states that the principal activities of the consolidated entity during the reporting period were "exploration and evaluation of the Consolidated Entity's exploration projects." The FY2025 Annual Report described principal activities as the progression of permitting at San José, with diversification into gold-silver-copper exploration. The Chair's Letter (21 Sep 2026) frames the company as having "embraced change", pivoting to copper-gold-molybdenum assets in the United States supplemented by a greenfield tin project in Australia, while preserving rights in Spain through a new Investigation Permit application and an appeal. ### Independent characterisation | Dimension | Characterisation | |---|---| | Business model | Acquire low-cost options over prospective or historic mineral assets; explore; define resources; monetise via sale, JV or development | | Revenue model mix | 0% product / 0% service / 0% subscription / 0% licensing. 100% of income is interest and grants (FY2026: interest only) | | Value-chain position | Upstream: greenfield/brownfield exploration. Historically planned vertical integration at San José (mine-to-lithium hydroxide on site) | | Customer types | None currently. San José was designed to supply battery-grade lithium chemicals to the European EV battery supply chain; no offtake agreements are disclosed as current | | End-markets (prospective) | Copper (electrification, grid), molybdenum (steel alloys, energy infrastructure), tin (solder/electronics), gold/silver (precious metals), lithium (EV batteries) | | Funding model | Equity placements (first since 2020 was the June 2026 A$2.25M placement); historically government grants (PERTE, since returned) | Infinity Metals is a pre-revenue, early-stage exploration company with an optionality-driven portfolio. It generates no product, service, subscription or licensing revenue. Its only income is interest on cash balances (A$23,911 in FY2026) and, historically, R&D tax incentive grants (A$102,340 in FY2025; A$264,410 in FY2024). Value creation depends on (a) exploration discovery and resource definition on newly optioned US and Australian projects, (b) any residual value that can be salvaged from San José via appeal, a new permit or a negotiated outcome, and (c) access to equity capital. ### Project portfolio summary (as at October 2026) | Project | Location | Commodity | Interest | Stage | Carrying value 30 Jun 2026 | |---|---|---|---|---|---| | Swansea | La Paz County, Arizona, USA | Copper | Option to acquire 100% (34 claims) + 16 lode and 4 placer claims staked 100% (Aug 2026) | Historic mine; pre-drilling baseline work | Not separately disclosed (option) | | Tule Canyon | Esmeralda County, Nevada, USA | Molybdenum-copper (porphyry) | Option to acquire 100% of Chandler Palm LLC (44 claims) | Historic drilling; field work H2 2026 | Not separately disclosed (post balance date) | | Yambacoona (EL9697) | ~60 km east of Bourke, NSW, Australia | Tin (lithium prospective) | 100% | Greenfield; air-core drilling approval sought | Included in A$208,967 total E&E | | Highland (Bindi EL7071, Mitta EL7072 and others) | Eastern Victoria, Lachlan Fold Belt | Gold-silver-copper | 100% | Early-stage mapping and sampling | Included in A$208,967 total E&E (part-impaired FY2026) | | San José | Cáceres, Extremadura, Spain | Lithium (mica-hosted, hard rock) | 75% via TEL (25% Saopse Minería S.L., formerly Valoriza Minería) | Mining licence application rejected 4 Aug 2026; appeal and new Investigation Permit application lodged | A$nil (impaired FY2025) |

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2010
Subiaco, Australia
Indoor

Indoor Skydive Australia Group Limited

Premium
Information Technology

| Field | Detail | Source | |---|---|---| | Current legal name | xReality Group Limited | [AR22; P26] | | Former name(s) | Indoor Skydive Australia Group Limited ("ISA Group"; ASX: IDZ) | [AR21] | | ACN / ABN | ACN 154 103 607 / ABN 39 154 103 607 | [AR21; P26] | | Founded / incorporated | Founding directors appointed 4 November 2011; tax-consolidated group effective 1 November 2011 | [AR21] | | Incorporation jurisdiction | Australia (public company, domiciled in Australia) | [4E25] | | Registered office / principal place of business | 123 Mulgoa Road, Penrith NSW 2750, Australia (co-located with iFLY Downunder) | [AR22; P26] | | Operator XR headquarters | New ~740 m² facility in Brookvale, NSW (secured during Q2 FY26) | [Q2-26] | | Exchange / ticker | ASX: XRG (formerly ASX: IDZ). Suspended from quotation since 30 Sep 2026 | [ASX-SUSP] | | ISIN | AU0000196065 (XRG line) | [MEDIA: financialfilings.com] | | CUSIP | Not applicable (no US listing); not publicly disclosed | — | | Listing date | Sources conflict: Pearler cites IPO 13 Dec 2012; financialfilings.com cites Jan 2013; an FNN article states listing in 2011; Stockhead refers to "listing in 2013". The most likely date is Dec 2012 / Jan 2013 | [MEDIA] | | Fiscal year end | 30 June | [All filings] | | Employees | Not publicly disclosed as a headcount in the sources reviewed. Proxy: employment expense rose from A$3.41m (FY22) to A$6.73m (FY25); 11 Operator XR hires in Q3 FY26 alone | [AR22; 4E25; Q3-26] | | Auditor | Felser Chartered Accountants t/as Accru Felsers (Sydney), appointed 13 June 2018; FY26 audit ongoing | [AR21; P26; ADJ] | | Share registry | Boardroom Pty Limited, Sydney | [AR22] | | Shares on issue | 663,547,525 at 30 Jun 2025 [4E25]; ~744m implied in 2026 (Market Index shows 9; 972; 017 shares = 1.34%) | [4E25; MEDIA] | | Market capitalisation | Not determinable while suspended. Last pre-halt quotes were about A$0.065–A$0.070/share (Jul–Sep 2026); InvestSMART shows ~A$53m; Simply Wall St showed A$37.3m at an earlier date. Implied ≈ A$48–52m at A$0.065–0.070 × ~744m shares (estimate) | [MEDIA] | | CEO | Wayne Jones (co-founder, CEO since foundation) | [AR22; P26] | | Chair | John Diddams (Non-Executive Chairman since 24 Jan 2022) | [AR22] | | Websites | xrgroup.com.au; operatorxr.com | [P26] | xReality Group is a Sydney-based micro-cap in the middle of a hard pivot. For over a decade it was an indoor-skydiving operator: the Australian licensee of the iFLY vertical-wind-tunnel brand, running tunnels at Penrith (NSW) and the Gold Coast (QLD). It now describes itself first as an enterprise software developer of mission-critical immersive simulation for military and law enforcement, through its wholly owned Operator XR subsidiary. Operator XR sells portable, offline-capable VR and mixed-reality tactical training systems (OP-2, MR-1, Interceptor C-UAS) on multi-year licence/support contracts. Most customers are US agencies: 108 of 118 customers at 30 June 2026. Operator XR revenue grew from A$0.6m (FY23) to A$7.8m (FY26), and ARR reached A$8.0m. The cash-generative iFLY tunnels (~A$7.3m revenue) are under strategic review. The FY26 restatement and the ASX suspension have introduced a significant governance and credibility overhang [P26; ADJ]. --- ### What the company does xReality Group operates two businesses, reported as segments, plus a corporate cost centre [4E25]: 1. **Enterprise (Operator XR).** This segment designs, develops, sells and supports immersive training and simulation systems for defence, law enforcement, corrections and "Tier 1" security customers. The flagship OP-2 system is a VR tactical trainer. Trainees use their own service weapons converted to dry-fire with recoil, and a 1–8-trainee system ships in a single transit case of under 25 kg that runs fully offline without IT support [P26]. The newer MR-1 overlays virtual threats onto real-world locations (bases, shoot-houses, transit hubs, critical infrastructure). The Interceptor C-UAS module trains counter-drone detect-identify-track-defeat sequences [P26]. Software includes a scenario-creator suite, instructor-controlled role-player avatars, after-action review and, increasingly, AI-driven adaptive characters [P26]. The Red Cartel VR production studio (acquired 2021) sits within this segment as the in-house content and software engine [4E25]. 2. **Entertainment (iFLY and FREAK).** The company operates two indoor-skydiving vertical wind tunnels under the iFLY brand: iFLY Downunder (Penrith) and iFLY Gold Coast. It also ran a chain of free-roam VR gaming venues under the FREAK Entertainment brand. The FREAK exit is "substantially complete": only FREAK Penrith remains, inside the iFLY Downunder lease. Advisers are assessing strategic options for the wind-tunnel assets [P26]. 3. **Corporate.** Group management, marketing, capital and centralised services. This is also where finance costs and AASB 16 lease charges are booked [4E25]. ### Business and revenue model | Revenue stream | Model | Recognition profile | Evidence | |---|---|---|---| | Operator XR hardware + software licence + support | Multi-year enterprise contracts. Hardware delivered upfront; software licensing and support recognised over the term. Reported as ARR and TCV | Mostly recognised monthly over contract terms. This creates deferred revenue (A$15.5m combined at 30 Jun 2026) | [P26; 4D26] | | Operator XR development contracts | Funded development, e.g., US DoD A$5.6m subcontract over 20 months, IP retained 100% by XRG | Percentage-of-completion / milestone | [Q4-26; P26] | | Government grants | R&D Tax Incentive (RDTI) refundable offsets; Industry Growth Program (IGP) grant of A$2.1m | Restated: grants relating to capitalised development are now deferred and amortised over the asset life (AASB 120) | [ADJ] | | iFLY flight sales | Per-flight retail (each flight was ~50 seconds, "up to $50", per 2018 media), packages, gift cards, Flight Club / coaching for professional and sport flyers, military freefall training | Point of service. Gift-card breakage recognised on expected redemption | [AR21; 4E25; MEDIA] | | FREAK VR sessions | Per-session ticketing at shopping-centre venues | Point of service (being wound down) | [AR22; Q3-26] | | Other | Food & beverage, merchandise, sub-let income | Point of sale | [AR21] | Mix: in FY26 (as lodged), revenue from customers of A$15.1m split A$7.8m Operator XR (52%) and A$7.3m Entertainment (48%). Grants of A$4.9m, as originally booked, took total income to A$20.0m [P26]. Under the 1 Oct 2026 amendment, grant income falls to A$0.9m and total income to A$16.1m [ADJ]. The product/service/subscription split is not disclosed formally. Management reports Operator XR ARR of A$8.0m against Operator XR recognised revenue of A$7.8m, which implies that recurring licence and support makes up most of recognised Operator XR revenue in steady state [P26]. ### Value-chain position Operator XR is vertically integrated. It owns the simulation engine, scenario content (via Red Cartel), weapons-integration kits, instructor tooling and AI layer. It integrates commercial off-the-shelf headsets and PC/streaming hardware ("Sentinel" mobile and fixed PCVR streaming) [P26]. Distribution is direct in the US (Operator XR LLC, Virginia) and Australia. Partners handle Europe (PROMOTEQ for the Swedish contract), Asia-Pacific (an unnamed APAC distributor for the Japan sale) and US defence-adjacent channels (Endurance Group, a veteran-owned US company, signed in 2022) [AR22; P26]. A non-binding MOU with Thales Australia (June 2026) aims to give access to larger prime-led military programs [P26]. In entertainment, XRG is a licensee/operator of SkyVenture's iFLY vertical wind tunnel technology and brand, not a tunnel manufacturer. Historical filings show royalty arrangements, including a "royalty holiday" asset [AR21; AR22]. ### Customer types and end-markets | End-market | Customer examples (disclosed) | Status | |---|---|---| | US state & local law enforcement | Texas Department of Public Safety (contract up to A$5.7m, Aug 2025); Colorado sheriff's department; LA SWAT trial; units in 38 US states | Core growth segment; 108 US customers [P26; 4D24 via MEDIA] | | US federal / DoD | US DoD subcontract (A$5.6m, completed May 2026); first commercial MR-1 sale to a separate DoD customer (Apr 2026) | Emerging [P26] | | Australian law enforcement | Western Australia Police Force (contract up to A$1.7m incl. GST, Nov 2022) | Reference customer [4E23] | | Australian Defence | Australian Army concept-evaluation purchase (Jun 2023) | Early [4E23] | | International military | Swedish Armed Forces end-user via PROMOTEQ (~A$450k, May 2026) | First NATO contract [P26] | | International government | Japanese government agency via APAC distributor (Feb 2026 PO) | First Asia sale [P26] | | Consumer leisure (Australia) | Tourists, families, groups, schools, corporate events | Mature, stable [P26] | | Professional/sport flyers & military freefall | Flight Club members, ADF freefall training | Niche within iFLY [AR21] | ### Company's own description vs independent characterisation **Company's own framing (paraphrased):** In its FY26 materials, xReality presents itself as a developer of enterprise software for mission-critical simulation for military and law enforcement. Operator XR is its "core growth asset", described as portable, secure, immersive training sold mainly into the US. Entertainment is a stable, cash-positive legacy business [P26]. **Independent characterisation:** XRG is better described as a sub-scale, hardware-enabled defence/LE training-simulation vendor attached to a leveraged leisure-property business. Three features stand out: **Capital-heavy balance sheet:** At 30 June 2026 the balance sheet was dominated by tunnel PP&E (A$17.8m) and right-of-use assets (A$12.5m), against lease liabilities of A$14.9m [P26]. **Software revenue still building:** Operator XR revenue is growing fast but is still only about half of group revenue. Reported profitability has depended on capitalised development and grant income: the restatement removed A$3.9m of FY26 grant income and turned EBITDA from +A$3.8m to −A$1.3m [ADJ]. **Cash conversion is genuine:** Operating cash inflow of A$5.5m in FY26 is unaffected by the restatement, largely because customers prepay multi-year contracts [P26; ADJ].

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2011
Penrith, Australia
Impact

Impact Minerals Limited

Premium
Information Technology

| Field | Detail | Source / note | |---|---|---| | Legal name | Impact Minerals Limited | FY2025 Financial Statements | | Former names | None identified | Not publicly disclosed in sources reviewed | | ABN | 52 119 062 261 | ASX releases | | Incorporation date | 31 March 2006 | IBISWorld company record; Dr Michael Jones listed as director since 31 March 2006 (FY2025 Directors' Report) | | Incorporation jurisdiction | Australia (Western Australia home exchange: Perth) | FY2025 Financial Statements, Corporate Directory | | Registered office / HQ | 9 Richardson Street, West Perth, WA 6005, Australia | FY2025 Financial Statements | | Telephone | +61 8 6454 6666 | FY2025 Financial Statements | | Primary listing | ASX: IPT | ASX | | Other quotations | Berlin: IUB; US OTC: IPPTF (secondary, unsponsored quotations per data vendors) | TipRanks; Zonebourse | | Listed options | IPTOC (exercise A$0.015 pre-consolidation, expiry 28 Sep 2027 — terms adjusted for consolidation); new options from Sept 2026 rights issue exercisable at A$0.06, expiring 17 March 2029 | ASX releases; Small Caps, 28 Sep 2026 | | ISIN | AU000000IPT4 (third-party); supplied CA45257A1021 is incorrect | See 1.1 | | CUSIP | Not applicable (non-US issuer) | — | | Fiscal year end | 30 June | FY2025 Financial Statements | | Auditor | Hall Chadwick WA Audit Pty Ltd (Subiaco, WA); lead audit director Mark Delaurentis CA (FY2025) | FY2025 Financial Statements | | Share registry | Automic Group, Sydney | FY2025 Financial Statements | | Company Secretary | Arron Canicais (appointed 30 November 2023) | FY2025 Directors' Report | | Employees | Not publicly disclosed. FY2025 wages and salaries were only A$184,837 and the Managing Director was engaged under a consultancy agreement, indicating a very small employed headcount supplemented by consultants and contractors | FY2025 Financial Statements Note 3(b) | | Employee 3-year trend | Not publicly disclosed | — | | Shares on issue | 516,783,796 at 30 June 2026 (post-consolidation); approx. 68.9 million new shares issued under the September 2026 rights issue, implying roughly 585–590 million shares on issue as of the dossier date (derived) | June 2026 Quarterly Activities Report (via Kalkine); Small Caps, 28 Sep 2026 | | Market capitalisation | A$20.15 million at 30 June 2026 (516.8m shares at A$0.039). At recent prices of about A$0.025–0.029 and ~586m shares, the derived current market capitalisation is approximately A$15–17 million; InvestSMART displayed ~A$15 million in September–October 2026 | June 2026 Quarterly; InvestSMART | | Cash | A$2.082 million at 30 June 2026, before the ~A$2.205 million (gross) September 2026 rights issue | June 2026 Appendix 5B | | Debt | No borrowings; lease liabilities only (A$323,125 at 30 June 2025) | FY2025 Financial Statements Note 17 | | Website | www.impactminerals.com.au | Corporate Directory | | Current leadership | Jim McKerlie, Executive Chair (independent Non-Executive Chair from 8 June 2026; leading the company following the MD's departure effective 25 September 2026); CEO search under way | ASX release 9 June 2026; Small Caps, 28 Sep 2026 | Impact Minerals is a Perth-based, micro-capitalisation critical-minerals developer in transition from a diversified generalist explorer into a high-purity alumina (HPA) company. Its strategic core comprises two complementary HPA pathways. The first is the 80%-owned Lake Hope project in Western Australia, a shallow, high-grade aluminous salt-lake clay deposit with a June 2025 Pre-Feasibility Study modelling 10,000 tpa of 4N HPA, a post-tax NPV of A$1.165 billion and pre-production capex of A$259 million, now moving to Definitive Feasibility Study. The second is a 50% equity stake in Alluminous Pty Ltd, owner of the patented HiPurA® processing technology, whose September 2026 scoping study favours a staged 2,000–4,000 tpa plant on the US Gulf Coast. Optionality is added by a sulphate-of-potash and hydrochloric-acid opportunity at Salmon Gums, a 30% free-carried interest in the Commonwealth–Silica Hill gold-silver project, and large Broken Hill and Arkun-Beau landholdings. The company is entirely equity-funded, with limited cash and a leadership transition under way. --- ### What the company does Impact Minerals acquires, explores and evaluates mineral tenements in Australia, and since 2023 has concentrated its capital and management attention on developing a vertically integrated HPA business. HPA (aluminium oxide of 99.99% purity or higher, "4N") is a specialty material used in LED substrates (synthetic sapphire), lithium-ion battery separator coatings and cathode materials, semiconductors, advanced ceramics and optical applications. HPA is on the Australian Critical Minerals List. The company's own characterisation, per the FY2025 Directors' Report, is that its principal activity during the year was exploration for deposits of nickel, gold, copper and platinum group elements, together with its right to earn an 80% interest in the Lake Hope HPA Project. The FY2025 Annual Report narrative positions Lake Hope as the "flagship" and frames the Alluminous investment as a strategic addition creating a pathway to an integrated HPA business. More recent company communications (June–September 2026) describe Impact as transitioning "from explorer to critical minerals producer" and "from developer to producer". ### Business model and revenue model Impact has no product sales and generates no operating revenue. Its "revenue" line in the statutory accounts consists solely of interest income (A$78,917 in FY2025; A$115,899 in FY2024), with other income comprising Research and Development Tax Incentive refunds (A$513,426 in FY2025; A$394,794 in FY2024) and minor other items. The business model is that of a resource developer: raise equity, spend on exploration and studies, and create value through (a) resource definition and de-risking leading to a development decision, (b) project-level farm-outs and joint ventures (e.g., Kuniko on Commonwealth), (c) asset sales retaining royalties (e.g., Blackridge, Orange Minerals), and (d) equity investment in technology vehicles (Alluminous). The prospective future revenue model, should Lake Hope or Alluminous reach production, would be the sale of a specialty chemical product (4N HPA, priced in the PFS at US$22,000/t) under offtake agreements with battery, LED and semiconductor supply chains, with by-product revenue from sulphate of potash (SOP). The Salmon Gums opportunity envisages SOP fertiliser and hydrochloric acid as primary products. The product/service/subscription/licensing mix is therefore 100% prospective product sales, with possible technology licensing optionality through Alluminous (not disclosed as a stated strategy). ### Value chain position Impact is positioned at the upstream end (mineral feedstock at Lake Hope) with a deliberate push into midstream chemical processing (its patented Playa One Sulphate Process for Lake Hope clays, and the HiPurA process via Alluminous). The Lake Hope concept involves mining shallow lake clays and trucking concentrate to a processing facility near Perth; the Alluminous concept uses purchased alumina-based chemical feedstock rather than mined ore, positioning it as a pure midstream processor. The stated long-term aim is vertical integration: Lake Hope as feedstock, HiPurA as a modular processing route. ### Customer types and end-markets No customers or offtake contracts have been disclosed. Prospective customers are HPA consumers: lithium-ion battery materials producers (separator coatings, cathode coatings), LED/sapphire substrate manufacturers, semiconductor and electronics manufacturers, and advanced ceramics producers. The only named counterparty engaged in product qualification is Charge CCCV LLC (C4V), a US battery-technology company that received approximately 15 kg of HiPurA HPA from the Alluminous Perth pilot plant for testing in early 2026 (Small Caps; ASX release on Alluminous/C4V collaboration, 19 December 2025). For SOP, end-markets would be specialty (chloride-free) fertiliser users; for hydrochloric acid, industrial chemical users including mineral processing. ### Independent characterisation Stripped of promotional framing, Impact is a cash-constrained junior with a portfolio of options rather than an operating business. Its value rests overwhelmingly on (i) the technical and commercial credibility of the Lake Hope PFS and the Playa One process at pilot scale, and (ii) the ability of Alluminous to demonstrate HiPurA at scale and secure customer qualification. The gap between modelled project NPVs (A$1.165 billion for Lake Hope, A$518 million for Alluminous at 100%) and a market capitalisation of roughly A$15–20 million reflects the market's heavy discount for funding risk (A$259 million Lake Hope capex versus ~A$2 million cash), technology-scale-up risk, HPA price uncertainty, and dilution. The September 2026 departure of the founding Managing Director and the launch of a strategic review add execution uncertainty but may also presage a sharper focus.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2006
West Perth, Australia
Image

Image Resources NL

Premium
Information Technology

**Data-quality flag on the input list:** The ISIN supplied (CA45245E1097) has a Canadian "CA" prefix. It does not match this Australian no-liability company. The ASX-listed Image Resources NL trades under ISIN AU000000IMA1, which is the identifier used by market-data services. The supplied ISIN should be corrected in the master list. **What it is:** Image Resources NL is a Perth-based, single-asset mineral sands producer. It mines and sells zircon-, titanium- and monazite-bearing heavy mineral concentrate from the 100%-owned Atlas mine, about 170 km north of Perth in Western Australia's North Perth Basin. **Track record:** Its predecessor operation, Boonanarring, ran for about five years and produced roughly 1.17 Mt of HMC. It generated close to A$800M in gross revenue. That track record funded dividends and the debt-free build of Atlas. **Asset base:** Image controls about 1,237 km² of mineral sands tenure and a total Mineral Resource of about 6.4 billion tonnes containing about 101 Mt of heavy minerals. This includes the very large McCalls and Mindarra Springs ilmenite deposits. **Optionality:** It is also developing a hydrogen-based synthetic rutile process and a small gold project, Erayinia King (139 koz inferred). **Current state:** The investment case is now defined by distress rather than growth: weak titanium-feedstock prices, a A$53M impairment, near-exhausted Atlas reserves, a prepayment facility owed to its Chinese offtakers, a CEO departure and a formal strategic review. **Market view:** The market values the company at roughly A$20–25M. --- ### What the company does Image Resources is an exploration, development and production company focused on heavy mineral sands in Western Australia. **Production model.** The company runs a "mine-and-concentrate" model: - Ore is dry-mined using excavators and trucks. - It is processed through a wet concentration plant (WCP) that separates the valuable heavy minerals from sand and clay. - The resulting HMC is trucked to port and shipped in bulk to offtake customers in China. **HMC composition.** The HMC is a mixed product containing: - zircon; - rutile; - leucoxene; - ilmenite; - monazite, a rare-earth-bearing phosphate. Image does not currently operate a mineral separation plant. Separation of the HMC into individual mineral products, and any downstream processing, is carried out by the customer. ### Company's own description In its CY2025 annual report and quarterly reports, the company describes itself in three ways: - an Australian mineral sands miner; - a producer and supplier of mineral sands and critical minerals (titanium dioxide feedstocks, zircon and monazite); - a company with a value-adding technology strategy built around upgrading ilmenite to synthetic rutile. It refers to the end of Atlas mining as the close of its "Chapter 1". "Chapter 2" growth involves: - new mineral sands developments (Durack, Yandanooka, Bidaminna, McCalls); - mineral separation; - synthetic rutile production using hydrogen. ### Business model and revenue model | Dimension | Characterisation | |---|---| | Revenue type | 100% product sales (bulk HMC shipments). No service, subscription or licensing revenue. | | Pricing | Market-linked. HMC prices reflect the contained zircon, TiO2 and monazite at prevailing market prices. Revenue per tonne was A$389/DMT in Q1 2026 and A$414/DMT in Q2 2026 (Q2 2026 Quarterly). | | Customers | Two long-standing Chinese offtake partners. Shantou Natfort Zirconium & Titanium Co., Ltd holds a life-of-mine offtake. Billion Sunny Investment Limited is the other prepayment counterparty. Guangdong Orient Zirconic (OZC), linked to shareholder Orient Zirconic Resources (Australia), has historically also been an offtaker. | | Credit risk mitigation | Letters of credit supporting each bulk shipment before loading (Boonanarring/Atlas model as described in 2024). Customer prepayments (e.g., US$2.75M advance received in Q2 2026 for a July 2026 shipment). | | Financing linkage | A secured US$20M offtake HMC prepayment facility from Natfort and Billion Sunny. It is repaid by delivering about 25% of each shipment at no cost, with the remaining ~75% paid at market prices. Interest is 10% p.a., compounding monthly. | | Logistics | Atlas HMC has been exported via Geraldton Port (first shipment, April 2025). One trade-press article states Bunbury Port, a discrepancy; the company's first-shipment release referenced Geraldton. | ### Value chain position Image sits at the upstream extraction and primary concentration stage of the titanium and zircon value chains. **Downstream steps performed by others:** **Separation:** into zircon, rutile, leucoxene, ilmenite and monazite. This is done by the customer, e.g., Natfort in China. **Upgrading of titanium feedstocks:** Ilmenite is upgraded to synthetic rutile or chloride slag. **Pigment production:** Feedstocks are converted into TiO2 pigment by chloride or sulphate processes. **Zircon processing:** Zircon goes into ceramics (tiles and sanitaryware), zirconia and zirconium chemicals, refractories and foundry uses. **Rare earths:** Monazite goes into rare-earth processing. ### End-markets served (indirectly) | End-market | Mineral | Demand driver | |---|---|---| | Ceramic tiles, sanitaryware | Zircon (opacifier) | Chinese and global construction, housing | | Zirconium chemicals, zirconia | Zircon | Industrial, electronics, nuclear, dental | | TiO2 pigment (paints, plastics, paper) | Rutile, leucoxene, ilmenite | Construction, consumer goods, GDP | | Titanium metal / welding | Rutile | Aerospace, defence, welding rods | | Rare-earth magnets | Monazite (NdPr) | EVs, wind turbines, electronics | | Abrasives (potential) | Garnet | Waterjet cutting, blasting. Image began screening garnet from HMC in Q2 2026 and held 1,387 DMT at 30 June 2026. | ### Independent characterisation Image is best described as a micro-cap, single-mine, price-taking concentrate producer. Its economics are almost entirely determined by four factors: 1. zircon and titanium-feedstock prices; 2. the AUD/USD exchange rate; 3. ore grade; 4. diesel and haulage costs. **Strengths.** Its historical strength was operational. It delivered Boonanarring and Atlas on time and without external equity. Its customer concentration in two Chinese buyers provided reliable offtake and financing. **Weaknesses.** The same concentration now gives the offtakers considerable leverage. The company sells a mixed concentrate rather than separated products, so it captures a smaller share of value than integrated peers such as Iluka. **Valuation.** The company's large resource base (McCalls, Mindarra Springs, Bidaminna) has strategic value for a well-funded consolidator. However, it is largely un-monetisable on Image's own balance sheet.

Revenue$0.1B
EmployeesN/A
Market CapN/A
Founded1994
West Perth, Australia
IDP

IDP Education Limited

Premium
Information Technology

IDP Education is the world's largest listed international student-placement company and one of three co-owners of IELTS, the leading high-stakes English language proficiency test for study, work and migration. It earns commissions from more than 1,000 partner universities and institutions across Australia, Canada, Ireland, New Zealand, the UK, the USA and, since FY26, Malaysia and the UAE, for recruiting and placing international students, and it distributes and administers IELTS tests in its territories (including India, following the 2021 purchase of the British Council's India IELTS business). Smaller lines include English-language schools in Vietnam and Cambodia, and the IDP Connect digital-marketing, events and data business for universities. After a record FY24 (revenue A$1.04 billion), simultaneous policy tightening in all four major destinations has cut its placement volumes by roughly 45% in two years. Management is executing a multi-year cost and technology transformation, positioning IDP as the "quality" agent with superior visa-approval outcomes. --- ### Company's own description (paraphrased from "About IDP Education", FY26 Results Announcement, 20 August 2026) IDP describes itself as a global leader in international student placement and a co-owner of the world's most popular high-stakes English test, IELTS. It says it blends human expertise with digital technology to help people gain admission to their preferred course, sit an English test, or study English in IDP schools, supporting customers from course search through to commencement. It cites partnerships with more than 1,000 quality universities and institutions across Australia, Canada, Ireland, New Zealand, the UK and the USA, and notes that its student-insight research is used by governments and organisations to inform policy. ### Independent characterisation IDP is a two-sided intermediary and assessment business sitting at the front end of the international education value chain: **Student Placement (≈46% of FY26 revenue):** A B2B2C model: students receive counselling, application processing, visa guidance and pre-departure support largely free of charge; IDP is paid a commission (typically a percentage of first-year tuition, recognised at census date) by the receiving institution. IDP increasingly layers on student-paid "Student Essentials" (accommodation, insurance, financial products) and institution-paid digital marketing, events, data and peer-to-peer marketing (The Ambassador Platform). Revenue is therefore driven by: number of placements (Application Processing Fees, or APFs) × yield (average revenue per placement), the latter reflecting tuition levels, commission rates, destination mix and FX. **English Language Testing (≈49% of FY26 revenue):** IDP is a co-owner of IELTS alongside the British Council and Cambridge University Press & Assessment (Cambridge English). IDP distributes and administers IELTS tests in its territories, earns the test fee and pays a royalty/fee to the test owner partnership (the "UCLES payable" referenced in the FY26 balance-sheet commentary). Volumes (FY26: 1.195 million tests) × yield (A$325 per test). India is the single largest market. **English Language Teaching (≈5%):** Course fees from IDP-operated English schools in Vietnam and Cambodia (108,400 enrolments in FY26). **Other (<1%):** Revenue model mix (FY26, analyst classification): service/commission revenue ≈ 46% (placements and associated services); transaction/fee revenue for assessments ≈ 49%; tuition revenue ≈ 5%. There is no material subscription or licensing revenue, although digital marketing contracts with universities have recurring characteristics. **Value-chain position:** demand generation and qualification of international students (upstream of universities), and gatekeeping assessment (IELTS) required by universities and immigration authorities (Australia, Canada's IRCC, UK Home Office via SELT recognition). **Customer types:** (1) prospective international students and test takers, predominantly from India, China, Nepal, Vietnam, Bangladesh, Pakistan, the Philippines, Thailand, Nigeria, Kenya and other source markets; (2) universities, colleges and schools in destination countries; (3) migration applicants and professional-registration candidates (IELTS General Training); (4) recognising organisations (13,500+ accept IELTS). **End-markets:** cross-border higher education (primarily Australia, UK, Canada, USA, NZ, Ireland), English proficiency testing for study/work/migration, and English-language tuition in Southeast Asia.

Revenue$0.5B
EmployeesN/A
Market CapN/A
Founded1969
Victoria, Australia
Identitii

Identitii Limited

Premium
Information Technology

The company now trades largely through its wholly owned operating brand and subsidiary, BNDRY Pty Ltd, which was incorporated on 3 July 2024 [FY25 4E]. Identitii is an ASX-listed microcap that makes regulatory-technology (RegTech) software. It helps regulated organisations prevent financial crime by collecting, structuring, securing and sharing compliance data. From 2014 to 2024 the company sold blockchain-derived payment-data platforms to banks and payments firms: Serra, then Overlay+, then the "Identitii Platform". Customers included HSBC, Mastercard and Standard Chartered. From FY25 it pivoted to BNDRY, a financial-crime compliance platform covering screening, monitoring, investigations and AUSTRAC reporting. BNDRY is aimed at cash-intensive Australian businesses, especially clubs and pubs that operate electronic gaming machines, and is distributed in partnership with Cherryhub. In February 2026 the company exited its legacy Overlay+ platform and the Mastercard contract. It now reports a single software segment, FY26 customer revenue of A$768k, annual recurring revenue of A$717k (Q4 FY26), negative net assets, and an auditor-flagged going-concern uncertainty. Its near-term future depends on a A$20M convertible note facility with The Blackstone Mercantile Group Ltd. SAC (a capital-markets group with no link to Blackstone Inc. identified in reviewed sources). The company targets operating cash-flow breakeven by the end of calendar 2027. --- ### Company's own description In its most recent filings the company describes its purpose as helping organisations build trust, protect their businesses and customers, and prevent financial crime through better use of financial data. It says it invests in technologies that make financial data more secure, more intelligent and easier to use [FY26 4E "About Identitii"]. The H1 FY26 Directors' Report describes Identitii as a software company. It helps financial-services businesses and other regulated entities securely manage information collection and sharing, which reduces the burden of data-compliance obligations [H1 FY26 4D]. The notes to those accounts state that its main product helps customers meet financial-crime reporting obligations, and that it operates in the RegTech industry, developing and licensing software for regulated entities [H1 FY26 4D, Note 1]. ### Independent characterisation | Era | Period | Proposition | Representative customers | |---|---|---|---| | Blockchain payments-data overlay | 2014–2020 | Serra and Overlay+: a private blockchain and tokenisation layer that "overlays" payment messages with enriched data, used for reconciliation, investigations and regulatory reporting | HSBC (global framework, DART tool, Australian licence), SWIFT proof of concept (2016), R3 CorDapp trial (2019) | | SaaS "Identitii Platform" / One Platform | FY21–FY24 | A consolidated cloud SaaS platform for AUSTRAC reporting, especially International Funds Transfer Instructions (IFTIs), and for requesting and sharing customer data in payment investigations | Mastercard, Novatti, Standard Chartered, Rabobank, Monoova, CoinJar [Oct 2023 AGM webinar slide] | | BNDRY financial-crime compliance | FY25–present | Screening, monitoring, investigations and reporting for AML/CTF programs, with a purpose-built version for clubs and pubs delivered with Cherryhub | 16 customer agreements reaching more than 125 businesses across banking, payments and hospitality [Q4 FY26 4C] | Identitii has turned from a bank-facing payments-data infrastructure vendor into a vertical SaaS compliance vendor for Australian AML/CTF-regulated small and mid-sized entities. ### Business and revenue model | Revenue type | Description | Evidence | |---|---|---| | Licence and usage fees | Recurring licence fees for platform access, plus usage-based charges | H1 FY26: A$354.6k of A$426.6k customer revenue [H1 FY26 4D Note 5] | | SaaS fees | Subscription fees on the SaaS platform | H1 FY26: A$66.0k (H1 FY25: A$52.0k) | | Professional services | Implementation and project work | H1 FY26: A$6.0k (H1 FY25: A$8.7k) | | Partner revenue share | Revenue shared with Cherryhub on the clubs and pubs solution | Cherryhub agreement (April 2025): the parties share revenue generated | | Non-operating support | Research & Development Tax Incentive (R&DTI) refunds, recorded as other income | FY26: A$680k; FY25: A$836k [FY26 4E] | **Revenue recognition mix (H1 FY26).** A$420.6k was recognised over time and A$6.0k at a point in time, so about 98.6% of revenue is recurring or ratable [H1 FY26 4D, derived]. **Forward reporting change.** Management said it will report recurring and usage revenue separately from Q1 FY27. It expects usage revenue to add materially to ARR [Q4 FY26 4C]. ### Value-chain position Identitii sits in the compliance-software layer between data sources and the regulator: **Data sources it draws on:** KYC and identity data, watch-lists, sanctions and politically exposed persons (PEP) data, gaming-system and membership data supplied through Cherryhub integrations. **Its own layer:** risk rating, monitoring, investigations, case management and pre-populated AUSTRAC reports (BNDRY's "Financial Crime Data Vault"). **Downstream:** regulated entities file reports to AUSTRAC. Identitii does not own gaming systems or identity-verification rails. It aggregates and orchestrates them. BNDRY says it connects to more than 1,000 data sources spanning more than 200 countries [Q4 FY26 4C]. ### Customer types and end-markets | End-market | Customer type | Status (FY26) | |---|---|---| | Hospitality and gaming (clubs, pubs, hotels running electronic gaming machines) | AUSTRAC reporting entities in the gaming-services designation | Primary growth vertical; distributed through Cherryhub | | Payments and remittance | Payment service providers, remitters, crypto exchanges | Legacy reporting customers being moved from Overlay+ to BNDRY | | Banking | Banks with AUSTRAC IFTI and threshold reporting obligations | Legacy plus some BNDRY adoption | | Card network (Mastercard) | Cross-border payments compliance information sharing | Exited 16 February 2026 [FY26 4E] |

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2014
Sydney, Australia
IconEnergy

Icon Energy Limited

Premium
Information Technology

Icon Energy is a micro-capitalisation, pre-revenue Queensland gas explorer whose value depends almost entirely on one tenure: ATP 855 (about 1,671 km²) in the Nappamerri Trough of the Cooper-Eromanga Basin, now the subject of Petroleum Lease application PL-1144. A joint venture drilled the permit between 2012 and 2016 with Beach Energy and Chevron, spending roughly A$165 million. It established a very large unconventional (shale, tight and basin-centred) gas resource and, in 2014, a conventional gas resource in naturally fractured, fault-associated reservoirs that the company calls the Keppel Gasfield. Icon has dropped the unconventional play and now targets non-fracked conventional development. It has no revenue, negative equity of A$4.5m, a A$4.9m well-restoration liability, and depends on funding from its founder-chairman. Its ASX listing lapsed in January 2026. Value therefore rests on a binary regulatory outcome: grant of PL-1144 under Queensland's one-off Lake Eyre Basin transition window. --- **Company's own description (AR25, paraphrased).** During FY2025 the principal activity was securing renewal of Authority to Prospect (ATP) 855 and advancing the application for Petroleum Lease PL-1144 over the whole ATP 855 area. No field operations were undertaken. The company's stated overall strategy is to move responsibly from explorer to gas producer. It describes the Keppel conventional gas resource as able to support Australia's 2050 emissions-transition pathway and help offset the forecast east-coast gas shortfall. **Business model.** Icon is a single-asset upstream gas explorer. It has no product, service, subscription or licensing revenue. Its intended model is upstream gas production from PL-1144 and sale into the eastern Australian gas market, either directly or through a farm-in partner. AR25 says the company will pursue farm-in opportunities and strategic partnerships to fund development and reduce funding risk. **Revenue mix.** **Value-chain position.** Upstream exploration and appraisal, at the earliest point of the gas value chain. Icon holds no midstream, processing or marketing assets. The Cooper Basin's Moomba processing hub and the South West Queensland pipeline network (owned and operated by third parties) would be the natural route to market. Icon has not disclosed any processing or transport arrangements. **Customer types and end-markets.** None contracted today. No extension beyond 30 June 2018 was found. Target end-markets are east-coast domestic gas buyers (industrial users, retailers, gas-fired generators) and indirectly the Gladstone LNG export complex. HY22 notes that management had identified "several eastern states markets" for ATP 855 gas. **Independent characterisation.** Icon is best described as a dormant-to-reactivating option on a single Queensland gas tenure, wrapped in a distressed corporate shell. The asset has real technical substance: six JV wells encountered gas, and Halifax-1 achieved what was then the highest shale-gas flow rate recorded in the Cooper Basin, 4.5 MMscf/d (PESA, 2017). The corporate vehicle, however, has: - negative net assets of A$4.51m; - a working-capital deficit of A$4.06m; - a material-uncertainty going-concern opinion in every year reviewed (FY2021–FY2025); - a three-person board; - no remunerated executives; - reliance on its founder for loans, equity and premises. The business is not an operating company in any conventional sense. It is a regulatory-tenure play with a contingent rehabilitation liability roughly 3.8 times its total assets.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1993
Bundall, Australia
NextEd

NextEd Group Limited

Premium
Information Technology

| Field | Detail | |---|---| | Legal name | NextEd Group Limited | | Former names | iCollege Limited (until December 2022); the iCollege business entered the ASX via a reverse takeover of DGI Holdings | | Incorporated | 2003 (per company profile on market data services; ACN 105 012 066 consistent with 2003 registration) | | Incorporation jurisdiction | Australia (public company limited by shares, Corporations Act 2001 (Cth)) | | Headquarters / registered office | Level 2, 7 Kelly Street, Ultimo NSW 2007, Australia (previously 205 North Quay, Brisbane QLD while operating as iCollege) | | Exchange / ticker | Australian Securities Exchange: NXD (formerly ICT) | | ISIN | AU0000258865 | | CUSIP | Not applicable / not publicly disclosed (no US listing) | | Original listing date | 24 August 2009 per third-party data (listing of the shell later used for the iCollege reverse takeover) | | Fiscal year end | 30 June | | Employees | Not disclosed in the FY26 Annual Report. A third-party aggregator cites 405 staff (date unknown). 3-year trend: not publicly disclosed; management disclosed "further reductions to our non-teaching workforce" in FY26 and a FY25 workforce restructuring | | Auditor | Pitcher Partners Sydney (engagement partner Rod Shanley, FY26) | | Share registry | MUFG Corporate Markets (AU) Ltd | | Shares on issue | 223,609,723 fully paid ordinary shares at 30 June 2026 (FY25: 222,116,114) | | Market capitalisation | Approx. A$17–21 million at A$0.076–0.094 per share (most recent verified trading range Jul–Aug 2026). One data service displayed A$0.050 after the FY26 result; this could not be reconciled and is flagged as a source conflict | | Website | nexted.com.au (legacy: icollege.edu.au) | | Chair | Sandra Hook (independent non-executive) | | CEO | Rob Arthur (from 19 August 2026; succeeded Mark Kehoe) | | CFO/COO | Andrew Nye | The listing identified as iCollege Limited (ASX: ICT, website icollege.edu.au) no longer trades under that name or ticker. The company renamed itself NextEd Group Limited in December 2022 to reflect its transformation after acquiring RedHill Education, and now trades on the ASX under the code NXD. NextEd Group is a small-cap Australian private tertiary education provider whose earnings are concentrated in international student education delivered through Greenwich College, a 20-year-old English language (ELICOS) and vocational (VET) brand operating a national campus network across Sydney, Melbourne, Brisbane, Perth, Adelaide and the Gold Coast. Around the Greenwich core sit three smaller businesses: the Academy of Interactive Technology (AIT) and allied design/coding brands (Technology & Design), a government-funded domestic vocational business focused on health and care, and Go Study Australia, an international student recruitment agency with heritage in Europe and Latin America. Formed by iCollege's 2021 scrip takeover of RedHill Education, the group peaked at A$111.4m revenue in FY24 before Australian student-visa tightening shrank its addressable market. Since FY24 it has cut its operating cost base by ~20%, pivoted the international mix from English toward higher-margin vocational courses, remained bank-debt-free, and now trades at a micro-cap valuation with negative tangible equity and a newly installed CEO. --- ### Company's own description (FY26 Annual Report, paraphrased) The FY26 Directors' Report states the Group's principal activities as the delivery of English language, hospitality, healthcare, creative digital technologies, management, marketing, computer coding, and interior design and styling courses, together with education recruitment agency services for international students; no significant change in the nature of those activities occurred during FY26. The financial report notes that the Company primarily operates businesses delivering accredited and non-accredited English language, vocational and higher education courses, plus an agency business placing international students into Australian tertiary study. The company's boilerplate describes NextEd as one of Australia's largest listed private education providers with campuses in Adelaide, Brisbane, Gold Coast, Melbourne, Perth and Sydney and recruitment offices worldwide, offering courses across English Language, Vocational and Higher Education in business, technology, design, hospitality, health and community services. ### Independent characterisation NextEd is, in economic substance, a leveraged bet on Australian international student policy. In FY26 the International segment (Greenwich) produced A$67.8m of the Group's A$88.9m revenue (76%) and A$15.7m of the A$15.3m group underlying EBITDA (i.e., more than 100% of group EBITDA before corporate costs of A$4.1m). The three other segments are sub-scale (A$6–8m revenue each) and collectively contributed A$3.7m of segment EBITDA in FY26. ### Business model and revenue model | Revenue type | Description | Approx. share of FY26 revenue | Source | |---|---|---|---| | Tuition fees – international students (ELICOS, VET, higher education) | Fee-for-service, paid largely in advance; recognised evenly over course delivery | ~76% (International segment) plus the international portion of T&D (~45% of T&D per presentation chart) | FY26 Results Presentation | | Tuition fees – domestic students | Mix of government-subsidised VET funding (notably South Australia for Individual Support) and fee-paying; domestic portion of T&D (bachelor/diploma programs) | Domestic Vocational 7.2% + domestic share of T&D | FY26 Annual Report | | Course materials and enrolment fees | Recognised over time from FY26 following a restatement correcting earlier point-of-invoice recognition | Not separately disclosed | FY26 Annual Report note 1.5 | | Agency commissions (Go Study) | Commission from education providers when a placed student commences; recognised at a point in time | 7.1% (A$6.3m) | FY26 Annual Report | The mix is overwhelmingly service revenue (education delivery); there is no product, subscription or licensing revenue of note. A defining feature is negative working capital: students pay tuition in advance, generating contract liabilities of A$35.1m at 30 June 2026 (A$40.1m restated at 30 June 2025). Management reports negative working capital of A$18.8m at June 2026 (FY26 Results Presentation). ### Value chain position NextEd operates at two points of the international education value chain: (1) recruitment/placement (Go Study, and Greenwich's own agent network), and (2) delivery (ELICOS, VET, and, since October 2025, higher education via the Greenwich Higher Education/AIT collaboration). It relies heavily on third-party education agents for international student acquisition; agency commissions are included in cost of sales. ### Customer types and end markets | Customer type | Segment | Notes | |---|---|---| | International student-visa holders studying ELICOS | International | ELICOS share of Greenwich international revenue fell from ~78% (FY24) to 41% (FY26) | | International student-visa holders studying VET (management, hospitality, health & care, community services, early childhood) | International | Vocational now 59% of International revenue (FY26) | | International and domestic students in IT, game design, 3D animation, interior design | Technology & Design | ~45% international / ~55% domestic by FY26 revenue (presentation chart) | | Domestic VET students, largely government-funded health and care | Domestic Vocational | 92% of segment revenue from health and care in FY26 | | Education providers (as payers of commissions) and prospective students in Europe/Latin America | Go Study | 64% onshore / 36% offshore revenue FY26 | International student source markets (Greenwich, FY26, share of students): Latin America excluding Brazil 31%, rest of world 16%, South-East Asia 14%, Brazil 11%, Korea 11%, Western Europe 9%, Japan 7% (FY26 Results Presentation).

Revenue$0.1B
EmployeesN/A
Market CapN/A
Founded2003
Ultimo, Australia
IceniGold

Iceni Gold Limited

Premium
Information Technology

Iceni Gold Limited is a Perth-based junior gold explorer. Its strategic value rests almost entirely on the 14 Mile Well Gold Project (14MWGP). This is a large contiguous tenement package (variously reported at about 850 km² at peak, about 645 km² in June 2026 and about 535 km² by September 2026) on the western side of Lake Carey. It sits between the Leonora and Laverton mining centres in Western Australia's Eastern Goldfields, and within about 75 km of several high-capacity operating gold mills. The company has no Mineral Resource, no production and no operating revenue. Its business model is discovery-led value creation: it generates targets through geochemistry, geophysics and drilling under transported cover, and then funds expensive drilling through two farm-in agreements with Gold Fields Limited. Gold Fields is also Iceni's second-largest shareholder at about 9.5%. One farm-in covers the 154 km² Guyer Trend (A$35M; inherited from Gold Road Resources). The other covers the 48 km² Everleigh Project (up to A$10M). A secondary asset, Welcome Creek, is a frontier copper-gold target in the Paterson/Officer Basin region. --- **What the company does.** Iceni Gold is a mineral exploration company. It acquires, explores and seeks to discover economic gold deposits in Western Australia. It does not mine, process or sell gold. Its activities are: - regional and prospect-scale geochemistry (soil, rock-chip and auger sampling, plus metal detecting for gold nuggets); - geophysics (aeromagnetics and gravity); - aircore (AC), reverse circulation (RC) and diamond (DD) drilling; - geological modelling; - tenement management and portfolio transactions such as farm-outs, acquisitions and relinquishments. **Company's own description (ASX "About Iceni Gold" boilerplate, 2026).** The company describes itself as an active gold explorer with two key projects in Western Australia. The main focus is the 14 Mile Well Gold Project in the Laverton Greenstone Belt, midway between Leonora and Laverton and within 75 km of multiple high-tonnage operating mills. It also holds exploration licences over the Welcome Creek gold-copper target about 140 km south of Telfer in the Paterson Province. The company emphasises that many of its tenements have never been systematically explored. It also highlights that its foundation work since May 2021 has identified priority target areas at Everleigh, Goose Well, Keep It Dark and the roughly 15 km Guyer Trend. (Paraphrased from ASX releases of 30 June, 4 August and 1 September 2026.) **Business model.** The model is the classic junior-explorer "discovery and monetisation" route. Equity capital is raised from sophisticated, institutional and strategic investors and spent on exploration. A discovery would create value through one of four routes: - defining a JORC Mineral Resource; - selling or joint-venturing the asset to a producer; - corporate takeover; - in theory, development. Development is less likely given how close several third-party mills are, such as Gold Fields' Granny Smith (about 25 km east) and Genesis Minerals' Laverton operations. Since December 2024 Iceni has used a hybrid "prospect generator" model. It farms out portions of its ground to a major producer, which funds exploration. Iceni keeps 100% of the remaining tenure and often acts as operator during the earn-in, which offsets some of its corporate and technical overhead. **Revenue model.** **Value chain position.** Iceni operates at the very top of the mining value chain: greenfield and brownfield exploration. It has no resource definition, feasibility, development, mining or processing operations. **Customers and end-markets.** Iceni has no customers in the conventional sense. Its "counterparties" are: 1. equity investors, who fund it; 2. major and mid-tier gold producers as farm-in partners or potential acquirers (currently Gold Fields); 3. if a discovery is ever monetised, the global gold market indirectly, priced off the spot A$ gold price. **Independent characterisation.** Iceni is a land-bank explorer that has been transformed by its partnerships. The original thesis (2021–2023) was a broad soil-sampling and drilling campaign across a large, under-explored package assembled by Executive Chairman Brian Rodan's private vehicle from 2017. That campaign produced several anomalies but no economic discovery, and the share price fell from IPO levels. The Guyer Trend breakthrough in 2024 changed the company's position. It attracted Gold Road Resources (A$35M farm-in plus a 9.9% placement, December 2024). After Gold Fields acquired Gold Road in 2025, Gold Fields signed a second farm-in at Everleigh (June 2026). The core problem remains balance-sheet thinness. Cash fell to about A$0.3M at 30 June 2026, and Iceni now depends on small, highly dilutive placements (A$0.70M at A$0.02 in August 2026). The investment case is a call option on discovery at Guyer, Everleigh, Goose Well and the newer 100% targets. Partner capital (up to A$45M across both farm-ins) can fund far more drilling than Iceni's own market capitalisation could support.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2020
West Perth, Australia
IperionX

IperionX Limited

Premium
Information Technology

IperionX is a pre-scale, US-focused titanium metal and critical-minerals company. It is building a vertically integrated domestic titanium supply chain that runs from mineral sands to finished components. Its core intellectual property is a family of patented powder-metallurgy processes. HAMR™ (Hydrogen Assisted Metallothermic Reduction) de-oxygenates titanium feedstock (scrap or mineral) into low-cost titanium powder. HSPT™ (Hydrogen Sintering and Phase Transformation) and related downstream processes turn that powder into near-net-shape titanium parts such as fasteners. The company says HAMR produces titanium powder at 40–70% lower cost than the incumbent Kroll process. Operations centre on a Titanium Manufacturing Campus in South Boston, Virginia. This campus moved to 24/7 production in the March 2026 quarter and targets an annualised run-rate of about 200 tpa of powder by end-CY2026, scaling to about 1,400 tpa with US Department of Defense (DoD/"Department of War") IBAS funding. Upstream, it owns the Titan Critical Minerals Project in Tennessee, whose DFS shows an after-tax NPV8 of US$813M. Commercially, the company is still at the pre-revenue/early-revenue stage and depends heavily on government funding. --- ### What the company does IperionX positions itself as an American titanium metal and critical materials company. It uses patented technologies to make high-performance titanium alloys from titanium minerals or scrap titanium, and claims lower energy use, cost and carbon emissions than conventional routes (company description as syndicated via FNN, July 2026). The business has two linked pillars. 1. **Titanium metal and products (Virginia).** HAMR converts titanium feedstock into titanium powder that the company says meets or exceeds Grade 5 (Ti-6Al-4V) quality parameters [Q4 FY26]. Downstream processes (HSPT™, THRM™ and powder metallurgy pressing) turn the powder into near-net-shape components. The company commissioned a six-axis powder metallurgy press in May 2026 and says it triples existing powder-metallurgy capacity [Q4 FY26]. Spherical powders for additive manufacturing are also in qualification [Q3 FY26]. 2. **Critical minerals (Tennessee).** The 100%-owned Titan Project near Camden, Tennessee is a near-surface, free-dig mineral sands deposit. It is designed to produce ilmenite, rutile, zircon and a Heavy Rare Earth Concentrate (HREC). The DFS supports an initial 14-year mine plan [DFS]. The adjacent Atlas property was acquired on 1 July 2026 for US$3M [Q4 FY26]. ### Business and revenue model | Revenue / funding stream | Status (latest disclosure) | Character | |---|---|---| | Titanium powder sales (direct) | Production in ramp-up; supports qualification programmes and direct powder requirements [Q4 FY26] | Product | | Near-net-shape titanium components (fasteners, pump/valve parts, defence parts) | Prototype and qualification orders; US Army GVSC prototype fastener order for the Joint Light Tactical Vehicle (JLTV), July 2026 | Product (engineered) | | US Government contracts and awards | IBAS US$47.1M (fully obligated); DPA Title III US$12.7M; SBIR Phase III contract vehicle up to US$99M [20-F FY26 summary via Quartr] | Cost-reimbursement funding and contract revenue | | Mineral concentrates (ilmenite, rutile, zircon, HREC) | Pre-development; DFS complete, project finance needed | Future product | | Licensing of IP | No licensing revenue disclosed | Not publicly disclosed | The company's stated core growth opportunity is finished titanium components rather than powder. It made this point explicitly in its November 2025 response to Spruce Point. Management expects customer revenue to begin and scale in 2H CY2026 as qualification programmes convert to purchase orders [Q3 FY26]. ### Value chain position IperionX aims to cover the full chain: mineral sands mining (Titan/Atlas), then primary titanium metal powder (HAMR, which bypasses Kroll sponge and melting), then alloy powder, then near-net-shape and finished components (HSPT/press/AM). Its scrap-to-powder route also lets it take in titanium scrap; the US Government has transferred scrap to the company, including about 290 metric tonnes cited alongside a final US$4.6M DoW funding payment. ### Customer types and end-markets Target sectors disclosed: defence (US Army GVSC, DoD programmes), aerospace, automotive (Ford contract cited in Q3 FY26 materials), consumer electronics (spherical AM powders under qualification), and industrial uses such as pump and valve parts [Q3 FY26]. ### Independent characterisation IperionX is effectively a government-anchored industrial scale-up story. In FY2026 it carried a net loss of US$66.8M with no material revenue. Its main assets are (i) a process-technology portfolio now running continuously at small commercial scale, (ii) a de-risked but unfunded US critical-minerals deposit, and (iii) a strong policy tailwind from US efforts to re-shore titanium and rare-earth supply chains. The investment case rests on converting qualification work into recurring component revenue before the funding window closes. That conversion has not yet been demonstrated at scale.

RevenueN/A
EmployeesN/A
Market Cap$0.9B
Founded2017
Virginia, US
Huon

Huon Aquaculture Group Limited

Premium
Information Technology

Huon Aquaculture is a vertically integrated Tasmanian salmonid farmer. Its operations run from broodstock and hatcheries through land-based nurseries, marine grow-out, processing, value-added smoking and national distribution. The company was founded by the Bender family in 1986 and listed on the ASX in 2014. It built a distinctive identity around high-energy offshore farming, notably its self-designed "Fortress" pens in exposed Storm Bay, and around large-smolt strategies that shorten the time fish spend at sea. Biological shocks (a 2018 jellyfish bloom and warm summers) and COVID-19 price dislocation pushed the group into a A$128m statutory loss in FY2021. It was then sold to JBS, for which it became the first aquaculture platform globally. Under JBS ownership Huon is investing about A$130m to A$140m in recirculating aquaculture systems (RAS). In FY2026 it overtook Cooke-owned Tassal as Tasmania's largest producer by volume. Its operating environment, however, has become sharply more contested because of disease-driven mass mortalities, animal-welfare controversies and a state government moratorium on marine expansion. --- **What the company does.** Huon breeds, grows, harvests, processes and sells Atlantic salmon (*Salmo salar*) and ocean trout (sea-farmed rainbow trout). Its value chain is fully integrated: 1. **Breeding and broodstock.** For around two decades Huon took part in the CSIRO-led Tasmanian salmon selective breeding program. It has since moved to its own in-house breeding program to gain more autonomy over genetics (Tasmanian Country, reporting comments from breeding program manager Lewis Rands). A new A$20m RAS broodstock facility is being built at Lonnavale. 2. **Freshwater hatcheries.** Historically Huon produced fry at four hatcheries (Forest Home, Lonnavale, Springfield and Bridport) and on-grew fish at freshwater sites including Meadowbank and Millybrook (Hatchery International). 3. **Land-based nursery (post-smolt).** The Whale Point RAS nursery at Port Huon grows large smolts. An A$110m expansion will give capacity for more than 7 million fish and recycle 99% of water. 4. **Marine grow-out.** Leases in the Huon River and D'Entrecasteaux Channel, the high-energy Storm Bay sites (a 20,000-tonne lease allocation), and Macquarie Harbour on the west coast. 5. **Harvest and primary processing.** Southern operations around Hideaway Bay and Dover, and the Parramatta Creek processing facility in north-west Tasmania. 6. **Value-added processing and distribution.** Smoked salmon and ocean trout, fresh portions, and a processing and distribution facility at Ingleburn, NSW (opened April 2019) serving Sydney and the eastern seaboard. 7. **By-products.** A planned A$20m rendering facility to turn processing waste into fish meal and salmon oil. Whale Point sludge already goes to horticultural composting (Cherries Tasmania). **Revenue model.** Revenue comes essentially 100% from product sales: whole fish, fillets, portions, and smoked or value-added products. There is no material service, subscription or licensing revenue. Sales channels historically comprised: **Domestic retail:** (major supermarket chains, branded and private label) **Domestic wholesale:** (fish markets, foodservice) **Export:** (spot and contracted sales, mainly Asia) COVID-19 severely disrupted the wholesale and export channels in FY2020 (company disclosure as reported by SalmonBusiness). Export share has varied widely: - H1 FY2018: 29% of volume (3,710 t) exported - H1 FY2019: 94% of harvest sold in Australia - At the 2021 acquisition: JBS described about 15% of production as exported - 2025/26: Huon's supply was characterised as roughly evenly split between Australian and international markets (Tasmanian Country) **Customer types.** Australian supermarket chains, seafood wholesalers and fish markets, foodservice and restaurants, and Asian importers. Under JBS, Huon is explicitly targeting China, where it competes with Norwegian suppliers (SalmonBusiness, 2025). **Company's own description.** Huon's latest public self-descriptions (website and project pages) emphasise "continuous innovation", industry-leading technology, growing fish longer on land, and being a global leader in aquaculture. The last full annual report was the FY2021 report (Huon Aquaculture Group Limited, year ended 30 June 2021). No subsequent standalone annual report has been published. **Independent characterisation.** Huon is a mid-scale, high-cost-environment salmon farmer (about 35 kt HOG) operating at the biological margin of the species. Tasmanian summer water temperatures regularly exceed salmon comfort thresholds. This drives recurring amoebic gill disease (AGD), and the endemic bacterium *Piscirickettsia salmonis* has become a major mortality driver since 2025. The strategic response, both pre- and post-JBS, has been capital-intensive: - offshore high-energy sites - huge wellboats for freshwater bathing - RAS to cut marine exposure Under JBS, Huon gives a meat-dominated protein group an aquaculture option and diversification within its Australian platform. Its economics are now opaque to outsiders, however, because they are folded into JBS Australia.

RevenueN/A
Employees900
Market CapN/A
Founded1986
United States, North America
HRL

HRL Holdings Limited

Premium
Information Technology

HRL Holdings was a Brisbane-headquartered micro-cap that converted itself from a failed geothermal explorer (Hot Rock Limited) into a specialist testing, inspection and data-management group serving Australia and New Zealand. Its rebuild started with the 2014 purchase of Octief, a Queensland asbestos and hazardous-materials consultancy. It continued with the 2014–15 purchase of Precise Consulting, a New Zealand hazardous-materials testing laboratory. The decisive step was the November 2017 acquisition of Analytica Laboratories in Hamilton, New Zealand. Analytica was a niche chemistry laboratory with leading positions in mānuka honey authentication and dairy/raw-milk testing, and it roughly doubled group revenue. Around this core, HRL built a hazmat consulting arm, a Queensland geotechnical testing unit and the Octfolio cloud software platform. By FY2021 revenue was A$34.6m and underlying EBITDA was A$7.7m. HRL's niche laboratory franchise attracted ALS Limited, which bought it in 2022 for about A$82m to deepen its ANZ food and environmental testing footprint. --- ### What the company did HRL Holdings was a diversified environmental and laboratory services provider operating offices and laboratories across Australia and New Zealand. ALS's acquisition announcement (6 September 2022) described HRL as a provider of sampling, laboratory testing and data-management capabilities for the food, environmental and occupational hygiene industries. McCullough Robertson, HRL's legal adviser on the takeover, summarised HRL as specialising in integrated field sampling, laboratory analysis and cloud-hosted asset management. Third-party company profiles based on HRL's annual reports list four operating segments: 1. **HAZMAT services**: asbestos and hazardous-materials management, property contamination testing, workplace drug testing, environmental testing, on-site testing and monitoring. 2. **Food and Environmental Laboratory services**: honey testing, milk and dairy testing, food-origin testing, drugs-of-abuse laboratory testing, asbestos laboratory analysis, environmental laboratory testing, and other laboratory R&D services. 3. **Geotechnical services**: geotechnical investigation and study, temporary works design and inspection, construction-phase verification, earthworks supervision, soil/concrete/aggregate testing, and on-site mobile laboratory testing. 4. **Software services**: information-management software for asbestos and hazardous materials, field-management software, and customised workplace health and safety compliance applications (Octfolio). The Food and Environmental Laboratory segment generated the largest share of revenue, and New Zealand was the majority geographic source of revenue (moomoo company profile, derived from HRL annual reports). ### Business model and revenue model | Revenue model component | Characterisation | Evidence | |---|---|---| | Fee-for-test laboratory services (per sample) | Dominant revenue model; transactional and recurring through regulatory and export-certification programmes | Analytica honey, dairy, food-origin and environmental testing | | Consulting / field services (time-and-materials, project fees) | Hazmat surveys, asbestos management plans, air monitoring, contamination assessments | Octief (Australia), Precise Consulting (NZ) | | Construction materials testing (project-based) | Earthworks supervision, soil/concrete/aggregate testing tied to Queensland civil construction | Geotechnical segment | | Software (subscription / SaaS licensing) | Cloud-hosted asbestos registers and hazmat data platform | Octfolio | | Product sales / licensing of IP | Not a material disclosed revenue line | Not publicly disclosed | The exact revenue mix split between service, consulting and subscription revenue was not publicly disclosed beyond segment level. ### Value-chain position HRL sat in the testing, inspection and certification (TIC) value chain as an independent third-party laboratory and field-sampling provider. Its "integrated" model, which it marketed throughout its listed life, combined three steps: field sampling by consultants (Octief/Precise), laboratory analysis (Analytica and in-house asbestos laboratories), and data delivery through a cloud platform (Octfolio). The aim was to capture more of each client's compliance spend than a pure laboratory or pure consultancy could. ### Customer types and end-markets | End-market | Customer types | Key services | |---|---|---| | Food and agri-exports (NZ) | Honey producers and exporters, dairy processors, raw-milk suppliers, infant-formula exporters | Mānuka honey authentication, glyphosate and AFB (American foulbrood) testing, raw milk testing, export certification support via CAIQTest Pacific | | Occupational hygiene / built environment | Building owners, government asset owners, property managers, construction contractors | Asbestos surveys, air monitoring, hazardous materials registers | | Residential property (NZ) | Landlords, housing agencies, property managers | Methamphetamine residue testing (a material line until the 2018 market collapse) | | Civil construction (QLD) | Contractors, engineering firms, infrastructure owners | Geotechnical testing, earthworks supervision, materials testing | | Environmental | Councils, consultancies, industrial clients | Water testing (expanded via Water Testing Hawke's Bay), soil contamination | ### Company's own description vs independent characterisation **Company/acquirer description (paraphrased from the ALS release, Sep 2022):** an industry-leading provider of sampling, testing and data management for food, environmental and occupational hygiene markets, with Analytica described as an industry leader in honey and dairy testing and Octfolio as a fully integrated asbestos testing and data platform. **Independent characterisation:** HRL was a sub-scale roll-up with one genuinely advantaged asset. Analytica's specialist chemistry franchise in NZ honey and dairy produced the bulk of group earnings: Taylor Collison estimated core lab testing at about 80% of group earnings in 1H FY21, with 28% EBITDA margins. Around it sat lower-margin, more cyclical consulting and construction-testing units. The hazmat arm was profitable but competitive. Geotechnical was a persistent laggard. Octfolio was strategically interesting but small. The equity story therefore came down to Analytica's growth runway versus the drag from the rest. That structure explains why a strategic buyer (ALS) could pay a 95% premium and still acquire the business at a modest multiple of group EBITDA.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded2006
Brisbane City, Australia

Page 224 of 482

1…223224225…482

Page 224 of 482

Go to page
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo